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INTRODUCTION 
 
Siddha system of medicine is an earliest Indian system of medicine and it 
provides efficient service to people. Aim of the system is to keep the body and 
mind in a good condition.Most of the current modern scientists says about the 
aetiology of the diseases as incoherent life style. The siddha system of medicine 
has a specific  character having specially that it not only cures the disease but also 
prevent the disease  
The drugs in siddha are classified into Thavaram(herbal origin), Thathu   
(metal and mineral origin) and Jeevam (animal origin). 
  Any change in the cosmos is always contemplated in the human body. Both 
are formed  the basic five elements(Pancha boodhangal) i.e.,  
• Mann(earth),  
• Neer(water),  
• Thee(fire),  
• Vali(air)  
• vin(space). 
Hence, siddhar’s Sattamuni has stated that,  
“«ñ¼ò¾¢ø ‾ûÇ§¾ À¢ñ¼õ 
À¢ñ¼ò¾¢ø ‾ûÇ§¾ «ñ¼õ” 
These five basic elements combine to form a three thathus Vali,Azal and Iyam. 
• Vali-Air+space 
• Azal-Fire 
• Iyam- Earth+Water 
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"Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö ¦ºöÔõ á§Ä¡÷ 
ÅÇ¢Ó¾Ä¡ ±ñ½¢Â ÓýÚ" 
 
     -¾¢ÕìÌÈû 
 
When the natural harmony of the three thathus becomes altered, the 
resulting inbalance causes various diseases. Soothagavayu is caused by 
imbalance of Vali and Azal. 
Many siddhars like THIRUMOOLAR, YUGIMUNI, AGASTHIAR and 
DHARVANTHRI has given special importance to female health and various 
gynecological problems like irregular menstruation, amenorrhoea, dysmenorrhoea, 
infertility etc. 
In the recent days life style modification and diet changes are the major 
causes for diseases. 
By following the life signs of Siddhars we can prevent, cure and promote a 
healthy life. 
“ÁÚôÀ Ð¼ø§¿¡ö ÁÕó¦¾É Ä¡Ìõ 
ÁÚôÀ ÐÇ§¿¡ö  ÁÕó¦¾Éî º¡Öõ 
ÁÚôÀ ¾¢É¢§¿¡ö Å¡Ã¡ ¾¢Õì¸ 
ÁÚôÀ º¡¨Å ÁÕó¦¾ÉÄ¡Ìõ." 
_¾¢ÕãÄ÷ ¾¢ÕÁó¾¢Ãõ. 
 
In siddha SOOTHAGAVAAYU which has various symptoms like Irregular 
menstruation or amenorrhoea, lower abdominal pain and head ache. 
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The clinical features of Soothaga Vaayu may be correlated with PCOS 
(Polycystic Ovarian Syndrome) in modern aspect since it is one of the most 
common endocrine disorders .PCOS produces symptoms in approximately 7-10% 
of female of reproductive age(15-45 yrs).Almost 75% of women with irregular 
periods suffer from PCOS,50% of women with PCOS are obese. 
Nowadays people expects a strong relief without any side effects for the 
disease. So i believed that a herbomineral preparation gives the best solution. 
So I preferred to select Soothagavayu as my dissertation topic with 
Soothagathai Udaikkum Kasayam and Maeni Lavana Chooranam. I will put 
my efforts as much as possible to give the best solution. 
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AIM AND OBJECTIVE 
 
AIM OF THE STUDY: 
                                    The SOOTHAGA VAAYU(POLY  CYSTIC  OVARIAN  
SYNDROME) results in irregular menstruation, anovulation and infertility. The 
aim of my dissertation work  is to regulate the menstrual cycle and to restore 
ovulation  with the two siddha drugs SOOTHAGATHAI  UDAIKKUM  
KASAYAM and MAENI  LAVANA  CHOORANAM. 
OBJECTIVE OF THE STUDY: 
• To study the clinical course of the disease with observation on 
aetiology, pathology, diagnosis, differential diagnosis, prognosis, 
complication and treatment  by siddha aspect. 
• To screen the clinical methods of diagnosis by our siddhars and to 
know how the disease manifests due to deranged mukkutram, 
poripulankal, ezhu  udazh thathukal and envagai thervugal. 
• To have an idea about the incidence of the disease with age, 
occupation, economic status, habits, hereditary and clinical 
conditions. 
• To have detailed  clinical investigations. 
• To have a clinical trial on the disease “SOOTHAGA  VAAYU” 
with siddha medicines “SOOTHAGATHAI  UDAIKKUM  
KASAYAM” and “MAENI  LAVANA  CHOORANAM”.       
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• To evaluate the  
 Chemical (Qualitative) 
 Pharmacological(Ovulation Induced Activity), 
 Toxicological (acute & sub acute), 
 statisticals of trial medicines. 
• To handle the modern parameters to confirm the diagnosis and 
prognosis of the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
SIDDHA ASPECT 
Á¡¾Å¢¼¡Â¢ý ¦ÀÂ÷: 
 
  "Á¡¾Å¢¼¡ö §À÷¾¨É§Â ÅÌì¸ì §¸Ù 
   Á¡¾ó¾ ¦ÅûÇÁ¡ï ¦ºýÉ£Ã¡Ì 
  ---------------------------------------------- 
   Å¢Çí¸¢Â§¾¡÷ Á¡¾Å¢¼¡öô §ÀÕÁ¡§Á." 
-§À¡¸÷ ¿¢¸ñÎ 1200           
Page No 101 
 
• Á¡¾ó¾ ¦ÅûÇõ 
• ¦ºýÉ£÷ 
• Í§Ã¡½¢¾õ 
• þÃò¾õ 
• ¿¡¡¢ÁÕóÐ 
• àö¨Á 
• ºì¾¢ ¿¡¾õ 
 
 ±ýÀÉ Á¡¾Å¢¼¡Â¢ý ¦ÀÂ÷¸Ç¡Ìõ. 
 
 
Á¡¾Å¢¼¡Â¢ý þÂøÒ: 
 
"¾¢í¸ÙÚ Áí¨¸Â÷¸û ¦¸üÀ¡ºÂÁ¨¾ ¾¡í¸¢Â¢Õ º¢Å¢¨¸ÔñÎ 
º¢Å¢¨¸Â¢Õ Àì¸Óõ Å£º¢§Â ¿¢üÌÁ¾¢É¢ý¦È¡Õ ÌÆø ¿ÃõÒ 
Àí¸ÁÈ§Å¦ÂØõ «ÊÅÂ¢Ú §Â¡É¢Ôõ ÍüÈ¢ô À¢¨½óÐ ¦¸¡ñÎ 
À¸ÕÁ¾¢¦Ä¡Õ Ó¨É þÃò¾¡ºÂÁ¨¾ì ¸ùÅ¢ì ÌÅ¢ó¾¢ÕìÌõ 
  þí¸¢¾Á¾¡¸§Å ÁÚÓ¨ÉÂÐ «¡¢¨ÅÂ÷ ¦¸üÀ¡ºÂõ ÒÌóÐ 
     þÉ¢¾¡ÂÃÅ¢Û¼ Å¡ÂÇÅ¡¸§Å ãÅ¢ÃÄ¨ºóÐ ¿¢üÌõ 
 
  Áí¸ÇÁ¾¡Â¢ó¾ ¿¡¾ìÌÆø ÅÆ¢ Ãò¾¡ºÂò¾¢É¢ýÚ 
      ÁÈÅ¸Ä§Å ¸¡¡¢Ãò¾õ ÍÃó¾¢É¢ ¦¸üÀ¡ºÂò¾¢§Ä ¾¡ý 
  ¿¢¾¢ÓÁ¢Ð ¾ÅÈ¡Ð µ§Ã ÐÇ¢Å¢Øõ ¬Èïº¾¡õ ¿¡Ç¢§Ä 
      §¿º¦Á¡Î ÌÆøÅÆ¢ ‾Õ¸¢ÂÐ ¦ÅÇ¢Â¢§Ä À¡ÔÐ §Â¡É¢ÅÆ¢Â¡ö 
  À¾Á¡¸§Å Í¸§¾¸¢Â ÐÅ¡¸¢§Ä¡ âò¾ Ó¾ø ãýÚ ¿¡Ùõ 
        À¸Õ¾¢ü §Á¡Ã¡ü ¸ÆïÍ ¿¢¨È À¡Ô§Á" 
 
        - «¡¢¨ÅÂ÷ º¢ó¾¡Á½¢ 
 7 
 
 The physiology of Women’s menstrual cycle is illustrated in the Siddha 
literature magnificently as before modern technologies had been developed. The 
uterus of women is attached to the ovaries with fimbria on either side through the 
fallopian tube. The cycle for healthy women takes place with an interval of 30 
days. Endometrial shedding takes place for three days. The amount of blood lost in 
one cycle is calculated in the very old period itself as 32 ml for normal women. (6 
kazhanju (6 x 5.2) = 32 ml) 
Ý¾¸Å¡Ô [SOOTHAGA VAAYU] 
§ÅÚ ¦ÀÂ÷¸û:[SYNONYMS] 
• Ýº¢¸¡ Å¡Ô 
• þÕÐ ¿£÷¸ðÎ 
                            -Shambasivam Pillai 
              Page No 352&372 
þÂøÒ : [DEFINITION] 
 
 ¸ÕìÌÆ¢Â¢ø Å¡Ôõ «ì¸¢É¢Ôõ §ºÕÅ¾¡ø Á¡¾Å¢¼¡ö ¾¢ÃñÎ, ¸ÕìÌÆ¢ 
à÷óÐ, «ÊÅÂ¢üÈ¢ø ÅÄ¢ ¸ñÎ, ‾¼õÒõ ÅÂ¢Úõ ÀÕìÌõ µ÷ Ý¾¸ §¿¡ö. 
 
-Shambasivam Pillai 
 Page No 372 
 
§¿¡ö ¸¡Ã½í¸û : [AETIOLOGY OF KARPA ROGANGAL] 
  "Åïº¨É ¾ýÉ¢É¡Öõ ÁÕó¾£Î ¾ýÉ¢É¡Öõ 
  ¦Á¡ïº¢Î º¡£Ã§Åð¨¸ ÔÚ¾¢¦ºö ¾ñÊôÀ¡Öõ 
  «ïºÄ¡õ À¢û¨Çô §ÀÈ¢Ä¼í¸¢Â þÃò¾ò¾¡Öõ 
  Á¢ïº¢Â Å¡ÔÅ¡Öí ¸ÕôÀ§¿¡ö §Á×¦Áý§É" 
 
        - ¾ýÅó¾¢¡¢ ¨Åò¾¢Âõ  
Page No185 
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• Åïº¨É 
• ÁÕó¾£Î 
• «¾¢º¡£Ã¦ÅôÀõ 
• À¢û¨Çô§ÀÈ¢ø ¾í¸¢Â ÌÕ¾¢ 
• «¾¢¸Å¡Ô 
 
¬¸¢ÂÅüÈ¡ø ¸ÕôÀ§¿¡ö ‾ñ¼¡Ìõ. 
 
   
  "§Á¸Á¾¢É¡ø ÝðÊÉ¡ø þ¾Á¡É Å¡ÔÅ¡ø 
   ¸¢ÕÁ¢Â¢ý ²ÐÅ¡ø âò¾À¢ý ¸½Å§É¡§¼ 
   §ºÕÅ¾¢É¡§ÄÔõ ¸Î¿¨¼¸Ç¡Öõ ÍÁÎ ¦ÅÂ¢ø ¾¡ìÌÅ¾¢É¡ø 
    Å¢¾Á¡É ¿¡¾ÁÐ ÜÎõ Ì¨Èó¾¢Îõ ¦¸üÀÁ¢øÄ¡Ìõ" 
 
        - «¡¢¨ÅÂ÷ º¢ó¾¡Á½¢ 
• §Á¸ §¿¡ö 
• Á¢Ìó¾ ‾¼üÝÎ 
• Å¡Ô 
• ¸¢ÕÁ¢ 
• âò¾À¢ý ¸½Å§É¡Î Ò½÷¾ø 
• ¸Î¿¨¼ 
• ¦ÅÂ¢ø 
¬¸¢Â ¸¡Ã½ò¾¡ø Ý¾¸õ Ì¨ÈóÐ «øÄÐ «¾¢¸Á¡¸¢ ¦¸üÀò¨¾ «Æ¢ìÌõ. 
 
“ ÍÆÄ¡Áø ¦Àñ¸ÙìÌ ¦¸üÀ §¿¡ö¾¡ý 
ÝúóÐÅó¾ Å¢óÐÅ¨¸ ÂÆ¢ó¾ À¡Åõ 
Áïº¡Áü À¡Ä¸¨É ¦¸¡ýÈÀ¡Åõ 
  ÌØÅ¢Â¢Çõ À¢ïÍâôÀÈ¢ò¾ À¡Åõ 
§¸¡Å¢Éí¸û ÁÕÌõÀ¡ø ÌÊò¾À¡Åõ 
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Å¢¨ÇÅ¡É Å¢ÇõÀÂ¢¨Ã ÂÆ¢ò¾À¡Åõ 
§Á¾¢É¢Â¢ø ÁÄ¼¡É Å¢ó¨¾¾¡§É.” 
-Agathiyamunivar kanmakandam 300 page 36 
 
Ý¾¸Å¡Ô þÂøÒ: [CLINICAL FEATURES] 
 
§¸Ù§Á Ý¾¸ò¾¢ø Äì¸¢É¢ Å¡Ô 
   ¦¸ÎòÐÅ¢Î Á¡¾Å¢¼¡ö ¸ðÊ§À¡Ìõ  
¬Ù§Á ¸ÕìÌÆ¢Ôóò àóÐ§¾¸õ 
   «ôÀ§É Ô¾¢ÃÁÐ «ÊãÄò¾¢ø  
¿£Ù§Á Ý¾¸ò¾¢ø Å¡ö×§¾¡ýÈ¢ 
   §¿Ã¡É «ÊÅÂ¢Ú ÅÄ¢ôÒ¸¡Ïõ 
À¡Ù§Á ¾¨ÄÅÄ¢ìÌõ ÅÂ¢Ú¨ÇìÌõ 
   ÀìÌÅÁ¡ö ÁÕóÐñ½ò ¾£Õó¾¡§É. 
-Aathmaratchamirtham ennum  
vaithiyasara sangiragam.  
Page no:55 
• Ý¾¸ò¾¢ø Å¡Ôõ «ì¸¢É¢Ôõ §º÷óÐ Á¡¾Å¢¼¡ö ¸ðÊì ¸ÕìÌÆ¢ à÷óÐ 
Ý¾Å¡Ô §¾¡ýÈ¢î Ý¾¸õ Á¡Úõ §À¡Ð «ÊÅÂ¢Ú ÅÄ¢ìÌõ 
• Ý¾¸õ ¾ÎòÐì ¸¡Ïõ 
• ¾¨ÄÅÄ¢ìÌõ 
• ‾¼Öõ ¦ÀÕò¾¢ÕìÌõ 
“¾¡¦ÉýÈ ¦¸üÀò§¾¡Î  ¾¡¢ò¾¢Î §¸¡¨Ãì¸ðÊø 
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Å¡¦ÉýÈ Å¢òÐ§À¡§Ä Å¡Ô×õ ‾ÕÙõÀ¡Õ 
°¦ÉýÈ Àº¢¾¡ý §À¡Ìõ Ó¨Çò¾Ð¾¡ý  
                                    þ¨Ãîºø ‾ñ¼¡õ 
          Á¡¦ÉýÈ ¸Æ¢îºø Á£Ùõ ÅÕõ Ý¾¸Å¡ÔÅ¡§Á.” 
   -Agasthiyar vaithiya kaaviyam 1500. 
 Page no:32 
 
 
“º¢ò¾¡É ¸÷ôÀò¾¢ø §º÷ó¾¢Îõ þÃò¾ó¾¡ý 
Åò¾¡õ ‾ÕñÎ Å¡Ô§À¡ø µÊÎõ  
‾üÈ Àº¢§À¡Ìõ ‾Æý§È þ¨Ãó¾¢Îõ  
ÅüÈ¡ì ¸Æ¢îºÄ¡õ ÅýÝ¾¸ Å¡Ô§Å.” 
-Thirumoolar karukkidai vaithiyam-600.  
Page no:29 
 
• Àº¢Â¢ý¨Á 
• ÅÂ¢Ú þ¨Ãîºø 
• ¸Æ¢îºø 
 
“¸ñÎÀ¡÷ Ý¾¸ò¾¢ Ö¾¢Ãõ §À¡¸¡ 
   ¸¡§Ä¡Î ¨¸§ÁÖõ ¸ÎòÐì Ìò¾¢  
¦ºñÎÀ¡÷ ÅÂ¢üÈ¢§Ä §¾¡„ó¾í¸¢ 
   ¾¢Èðº¢ ÌýÁÅ¡Ô¦Å¡Î Ý¨Ä Â¡îÍ 
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¬ñÎÀ¡÷ Ý¾¸Å¡Ô Å¡îÍ 
   «À¡ÉÁ¡í ¸ÕìÌÆ¢ Â¢Ö¾¢Ãí ¸ðÊ 
‾ñÎÀ¡÷ ‾¾¢Ãò¾¢ø Å¡ö× ÜÊ 
   ‾ûÇí¸¡ø ¿¸ì¸ñ Ì¾Ä¡î§º.” 
-Birammamuni vaithiya soothiram 390. 
 Page:93 
 
• ¨¸ì¸¡ø ÅÄ¢ 
• ÌýÁõ 
• Ý¨Ä 
• Á¡¾Å¢¼¡ö ¸ðÊ ¦¸¡ûÙõ 
• ‾ûÇí¸¡ø ¿¸ì¸ñ½¢ø Ìò¾ø 
 
“¾¡É¡É Ý¾¸ò¾¢ý Å¡öÅ¢ý ¾ý¨Á  
   ¾¡§É «ì¸¢É¢ Å¡Ô Ý¾¸ò¾¢ø ¾í¸¢ 
Á¡§É Á¡¾Å¢¼¡ö ¸ðÊì¦¸¡ûÙõ 
   ÁÕ× Ý¾¸ ¿¡Ç¢ø Å¡ö×ñ¼¡õ 
¾¡É¡§Ã «ÊÅÂ¢Ú Òñ§À¡ø §¿¡Ìõ 
   ¾¨ÄÅÄ¢Ôñ¼¡õ ÅÂ¢üÈ¢ø §¿¡×ñ¼¡Ìõ  
¬É¡Öõ ÅÂ¢Ú¼Öõ ¾Êò¾¢ÕìÌõ 
   «È¢ÌÅ¡ö Ý¾¸ò¾¢ý Å¡ö× ¾¡§É.”   
  -Arivaiyar sinthamani. 
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• Á¡¾Å¢¼¡ö ¸ðÊ ¦¸¡ûÙõ 
• «ÊÅÂ¢üÚ ÅÄ¢ 
• ¾¨ÄÅÄ¢ 
• ‾¼ø ¦ÀÕò¾¢ÕìÌõ 
 
“À¡¾¦Á¡Î Ý¾¸Å¡ÔÅÐ ¾ý¨Á§¸û 
   Á¡¾Å¢¼¡ÂÐ Ì¨ÈÔ§Á 
Ò¸Ø¡¢Â ÅÂ¢Ú ¸ÉÁ¡¸¢Â¾¢ §Å¾¨É 
   «ÊÅÂ¢Ú Òñ§À¡ø §¿¡Å¡õ 
§À¡¾ÓÚ ¦ºýÉ¢ÅÄ¢ ‾îº¢Â¾¢§Ä ÌòÐ 
    þÕ ¦¸¡í¨¸ÂÐ Ô¨ÇÔ§Á  
§Á¡¾¢Â¾¢ ¾¡Â¢Õ ¨¸¸¡ø ¸ÎìÌ§Á  
    ¸¡ø Áñ¨½ÂÐ Ô¨ÇÔ§Á  
Ó¾¢Â ¿¡Å¡ÉÐ ÅØÅØôÀ¡Â¢Îõ 
    «ýÉõ Ì¨ÈóÐ ÅÕ§Á  
¿¢¾ÓÚ §ÁÉ¢ÂÐ Å¢ÇÚÁ¾¢ §º¡ÀÁ¡ö 
    ¦º¡üÀÉõ «¾¢¸¡¢ìÌõ.”    
-Arivaiyar sinthamani.  
 
• Á¡¾Å¢¼¡ö Ì¨ÈÔõ 
• ÅÂ¢üÚ ÅÄ¢ 
• ¾¨Ä ÅÄ¢ 
• Á¡÷Ò ÅÄ¢ 
• ¨¸ì¸¡ø ÅÄ¢ 
• ¿¡ ÅØÅØôÒ 
• Àº¢Â¢ý¨Á 
• «¾¢àì¸õ 
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OTHER TYPES OF KARPA NOIGAL SIMILAR TO 
SOOTHAGAVAAYU 
 
KARPA VAAYU: 
 
“¦À¡ÕÁ¢ Ãò¾ó¾¨É ÁÈ¢òÐô§À¡¾ Á¢¸×õ ÅÄ¢Ôñ¼¡í 
ÌÕ¾¢§ºÃ¡ ÅÂ¢ÚÅÄ¢§À¡í ¦¸¡ûÙí ¸÷ôÀó¾¨ÉÂÆ¢ìÌõ 
ÅÕÊÂ¢ÎôÒì Ì¨¼óÐ¨ÇÔ ÁÄò¨¾ Á¢¸×Á¢Úì¸¢ ¿¢üÌõ 
¦ÀÕ¸ô À¨½ìÌí ÌÅ¢Ó¨ÄÂ¡ö §Àºí ¦¸÷ôÀÅ¡ÔÅ¢§¾.”  
-Agasthiyar aayulvetham 1200. 
Page No 187 
• Á¡¾Å¢¼¡Â¢ø ÌÕ¾¢ô§À¡ìÌ Ì¨È¾ø 
• ÅÂ¢üÚ ÅÄ¢ 
• ¸÷ôÀò¨¾ «Æ¢ìÌõ 
• þÎôÒ ÅÄ¢ 
• ÁÄì¸ðÎ 
 
 
KARPA VIPPURUTHI: 
 
“ÜÈ¢¼§Å ¦¸üôÀÅ¢ü ÒÕ¾¢¾¡Ûõ 
   ÌÕ¾¢§À¡ø ÅÂ¢È¢É¢ø Ý¾í¸ðÎõ 
Á¡È§Å ¾¨ÄÅÄ¢ìÌõ Å£ðÎôÀì¸õ 
   ÅÂ¢üÚÅÄ¢ Â¢ÕÐ¨¼Ô Ó¨ÇÔ§Á¾¡ý 
º£È§Å ÒØò¾¢ÃñÎ ÁÄÁ¢ÕìÌõ 
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   º¢Í¦¸÷ôÀóò ¾¡¢Â¡Ð ×¼Ö¨ÇìÌõ  
¬È§Å Â¢ìÌ½í¸û ¾¡ÉÈ¢óÐ 
   «ôÀ§É ÁÕóÐñ½î º¢ò¾¢Â¡§Á.”  
                        -Aathmaratcahamirthmenum vaithiya sara sangiragam. 
          Page no:49 
    
• Ý¾¸¸ðÎ 
• ¾¨ÄÅÄ¢ 
• ÅÂ¢üÚÅÄ¢ 
• þÎôÒÅÄ¢ 
• ÁÄì¸ðÎ 
• ¸÷ôÀõ ¾¡¢Â¡Ð 
• ‾¼øÅÄ¢ 
 
 
KARPA SURONITHAM: 
        “¾¢ÃñÎ ÒÃñÎ ¸£úÅÂ¢üÈ¢ø ¾¢í¸û ÓØì¸¢øÅÄ¢Ôñ¼¡Ìõ 
 ÁÕñÎ ÌÕ¾¢ ÌÚ¸¢ÅÕõ Å¡öÉ£åÚ ÁÂí¸¢ÅÕó 
¾¢ÃñÎ º¢Ä¿¡ð º¢ì¸¢¿¢üÌõ ¾¢ÈÁ¡íì ¸Õ¨Å ÂÆ¢ôÀ¢ìÌ 
ÓÕñ¼ º¢Ä¿¡ð º¢ì¸¢¿¢üÌõ ¾¢ÃÁ¡í ¸Õ¨Å ÂÆ¢ôÀ¢ìÌ 
ÓÕñ¼ ¸÷ôÀî Í§Ã¡½¢¾¦Áý Õ¨ÃìÌí½í¸ñ¼È¢Å£§Ã.”  
-Dhanvanthiri vaithiyam.Page No 187 
 
• Ý¾¸ÅÄ¢ & ÌÕ¾¢ ÌÚ¸¢ ÅÕõ 
• Å¡ö ¿£åÈø 
• ÁÂì¸õ 
• ´Øí¸üÈ Á¡¾Å¢¼¡ö 
• ¸Õ¨Å «Æ¢ìÌõ 
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SOOTHAGA KIRANI: 
“Ý¾¸Á¡õ §À¡¦¾øÄ¡õ ÅÄ¢ò¾¢Ãò¾õ 
Å£úÅ¾üÌõ ¦º¡Ö ¿¡ìÌð 
§À¾¸Á¡öì ¦¸Î¾ôÀ¢ ÅÄ¢ì¸¢Ûõ 
Ý¾¸ì ¸¢Ã¡½¢ ±ýÚ§ÀÃ¡õ.”  
                       -Sarabenthirar vaithiyamuraigal. 
Page No 245 
• Ý¾¸ÅÄ¢ 
• ´Øí¸üÈ Á¡¾Å¢¼¡ö 
 
 
MUKKUTRAIYAL 
 
Tri dosha is otherwise called as muppini as they remain as doshas 
and form as the causative factor for the appearance of disease. This is only a part 
of the panjabootha thathuvam and forms the humoural pathology in siddha system 
of medicine similar to hormones in modern physiology.  
A right understanding of tri dosha theory in all its varied aspects is 
necessary for a rational diagnosis and effective treatment. 
 
"Å¡¾Á¡ö À¨¼òÐ À¢ò¾ ÅýÉ¢Â¡ö ¸¡òÐî §ºðÀ 
º£¾Á¡ö Ð¨¼òÐô À¡Ã¡ó §¾¸ò¾¢üÌÊÂ¡ ¨ÁóÐ 
â¾Å¢ó¾¢Â¡¨ÁÅ÷ â¨º ¦¸ñ¼Å÷À¡ø Å¢óÐ 
¿¡¾Á¡í ¸¢ÕðÊ½ ã÷ò¾¢ ¿Áì ¦¸ýÚõ Ð¨½Â¡Å¡§Ã" 
 
- §¾¨ÃÂ÷ ÁÕòÐÅ À¡Ã¾õ 
        (§¿¡ö ¿¡¼ø §¿¡öÓ¾É¡¼ø ¾¢ÃðÎ À¡¸õ 1 Àì¸ ±ñ. 97) 
 16  
 
Panchaboothams are manifested in the body as three vital forces. 
• Vaatham 
• Pittham 
• Kabham 
 
TRI 
DOSHAS 
SEATS  PROPERTIES FUNCTIONS 
1. VATHAM Below the naval, 
urinary bladder, 
intestine, pelvis, 
umbilical cord, thigh, 
bone, skin, nerve 
endings, joints, 
musculature, hair root    
Dryness, 
lightness, 
clearness, 
coolness, mobile 
formless. 
Stimulation, 
respiration, 
thinking, sensory 
functions, co-
ordination of the 
physical 
constituents, 
reflex actions. 
2. PITHAM Between the heart and 
naval, sweat, lymph, 
blood, stomach, urinary 
bladder, heart, saliva, 
eye, and skin. 
Dry, cold, light, 
subtle, keen, 
soft, liquid, 
bitter. 
Body 
temperature, 
digestion of food, 
vision, sweat. 
3. KABHAM  Above the heart, 
stomach, fat, sperm, 
uvula, bone marrow, 
blood, nose, nerves, 
eyes, joints.    
Heavy, cold, 
sweet, stable and 
slimy. 
It gives strength 
of joints, shiny 
appearance of 
skin, moistens 
food, cools the 
eye, softness, 
firmness. 
 
Vatham: 
 
It is said to be first originated from the natural element air and then with the 
combination of the other two elements, heat and water developed as vatha, and 
involution of typical type of synthetic chemical changes occur before it is 
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represented in the human body as a humour of vatha dosha. This is classified into 
ten varieties.  
TYPES OF 
VATHAM 
          FUNCTIONS IN 
SOOTHAGAVAAYU 
1. Piraanan It is mainly responsible for 
respiration and it is necessary for 
proper digestion and utilisation of 
food materials. 
Normal 
2.Abaanan This is responsible for all downward 
movements such as passing urine, 
stools, semen, menstrual flow etc. 
Irregular menstruation, 
constipation. 
3.Viyanan This is responsible for sense of 
touch, extension and flexion of the 
part of the body and distribution of 
the nutrients to various part of the 
body. 
Low back pain, lower 
abdominal pain.  
4.Uthaanan Responsible for all upward visceral 
movements such as nausea, 
vomiting etc., 
Normal 
5.Samaanan This aids in proper digestion and it 
controls the other types of vaayu. 
Normal  
6.Naagan  Helps in opening and closing of the 
eyelids.  
Normal 
7.Koorman Responsible for vision, lacrimation 
and yawing. 
Normal 
8.Kirugaran Induces appetite, salivation, all 
secretions in the body including 
nasal secretions and sneezing. 
Normal 
9.Thevathathan Induces and stimulates a person to 
become alert, get anger, to quarrel, 
to sleep. 
Normal 
10.Dhananjeyan Produces bloating of the body after 
death. It escapes on the third day 
after death bursting out of the 
cranium.  
_ 
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Pitham: 
This is said to be originated first from the natural element of heat 
and then with the combination of other two elements viz. air and water, developed 
as pitha and after the involution of synthetic chemical changes it is represented in 
the human body as a humour of pitha dosha. This is also sub –divided into five 
types.   
 
 
  TYPES OF PITHAM FUNCTIONS IN SOOTHAGAVAAYU 
1.Analagam It promotes appetite and 
helps indigestion. 
Normal 
2.Ranjagam It is responsible for the 
colour and contents of 
blood. 
Normal 
3.Praasagam It gives complexion to 
the skin. 
Normal 
4.Saathagam It controls the whole 
body and is held 
responsible for fulfilling 
a purpose. 
Lack of regular 
menstruation. 
5.Aalosagam It is responsible for the 
perception of vision. 
Normal 
 
Kabham: 
Kabham is said to be originated first from the natural element 
namely water and then with the combination of other two elements air and heat, it 
develops as kapha and after the involution of synthetic chemical changes it is 
represented in the human body as humour in kabha dosha. This kabha dosha is 
said to possess the destruction power. This is of its coldness which when markedly 
increased over laps other two doshas vatha and pitha which are responsible for the 
respiration, circulation of blood and maintain of head and remains as the signs of 
life with the result death occur.   
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TYPES OF 
KABHAM 
FUNCTIONS IN SOOTHAGAVAAYU 
1.Avalambagam Lies in respiratory organ, 
controls the heart and other 
kabhams. 
Normal 
2.Kilethagam Lies in stomach, makes the 
food moist, soft and helps 
indigestion. 
Normal 
3.Pothagam Responsible for the sensory 
perception of taste. 
Normal 
4.Tharpagam Present in the head and 
responsible for coolness of 
both eyes. 
Normal 
5.Santhigam Responsible for lubrication 
and the free movements of 
the joints. 
Low back pain. 
 
Generally tri dosha occupy Agni mandalam, Surya mandalam and 
Santhra mandalam respectively. Kabha is anabolic and vatha, pitha is catabolic 
properties. The tri dosha theory takes into consideration the principles of 
biological laws, the physiological workings, the chemical process and thathwic 
experiences which are so fundamental and the physical basis, all of which are 
effecting in a synthetic way the workings and activities of the human body. It is a 
pardonable temptation to presume that we may be right in calling this wonderful 
conception of the siddhas as the laws of vatha pitha and kabha, just as the law of 
Gravitation is an external principle that governs the universe.  
UDAL THATHUKKAL 
The saptha thadu constitutes the structure of the human body and its 
functions. Hence this may be compared to anatomy and physiology of modern 
system, along with the logic and philosophy in general. In modern medicine the 
human body is said to be constituted with the cells, tissues, muscles, tendons, fat, 
organs, bones, skin, net work of nerves, blood vessels, fluids like blood and 
hormones.    
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SAPTHA 
THATHUKKAL 
FUNCTIONS IN SOOTHAGA 
VAAYU 
1. Saaram It is responsible for the growth & 
development. It keeps in good sprit 
and it nourishes the blood. 
 
Tiredness  
2. Seneer  Blood imparts colour to the body & 
nourishes the muscle responsible 
for the ability, intellect of the 
individual. 
Hormonal imbalance. 
3. Oon  It gives shape to the body according 
to the requirement for the physical 
activity, nourishes fat & give 
plumpness. 
Cyst  
4. Kozhupu It helps lubrication of different 
organs. 
Low back pain, obesity. 
5. Enbu Supports and responsible for 
posture and movements of the 
body. 
Normal  
6. Moolai It fills the bony cavity and gives 
nourishment. 
Normal  
7. Suronitham It is responsible for the 
reproduction. 
Irregular menstruation. 
 
 
DIAGNOSIS OF SOOTHAGAVAAYU BASED ON SIDDHA SYSTEM 
According to siddha system the diagnosis of a disease is reached by 
the method Envagai Thervu or Piniarimuraimai 
“¾Ã½¢ÔûÇ Å¢Â¡¾¢ ¾¨ÉÂ‰¼¡í ¸ò¾¡ø 
¾¡ÉÈ¢Â §ÅñÎÁÐ ²¦¾ýÉ¢ø  
¾¢Ã½¢Â§¾¡÷ ¿¡Ê¸ñ¸û ºò¾ò§¾¡Î 
    §¾¸ò¾¢ý ÐÀ¡¢ºõ Å¡Éõ ¿¡ìÌ  
þÃ½ÁÄõ þ¨Å¸¦ÇðÎõ þ¾õÀ¼§Å 
     ¾¡ýÀ¡÷òÐì ÌÈ¢ôÒí ¸ñÎ 
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ÀÃÉÕÇ¡ü ¦À¡¢§Â¡÷¸ð À¡¾õ §À¡üÈ¢ô 
    ÀñÒ¾ÅÈ¡Áü ÀñÊ¾ï ¦ºöÅ£§Ã” 
-«¸Šò¾¢Â÷ Ì½Å¡¸¼ ¿¡Ê áø.  
        (§¿¡ö ¿¡¼ø §¿¡ö Ó¾ø ¿¡¼ø Part I) 
Àì¸ ±ñ:136  
The Envagai Thervu based is on 
 Poriyal arithal 
 Pulanaal arithal 
 Vinathal  
 
1. Pori- sensory organs                             
• Nose 
• Tongue 
• Eye 
• Skin 
• Ear   
 
2. Pulan – 5 senses 
• Odour  
• Taste  
• Vision  
• Touch  
• Sound  
 
3. Vinathal- interrogation 
Envagai Thervu: 
 
"¿¡ÊôÀ¡¢ºõ ¿¡¿¢Èõ ¦Á¡Æ¢Å¢Æ¢ 
ÁÄõ ãò¾¢ÃÅ¢¨Â ÁÕòÐÅÃ¡Ô¾õ" 
 
"¦ÁöìÌÈ¢ ¿¢Èó§¾¡ Å¢Æ¢¿¡Å¢ÕÁÄõ ¨¸ìÌÈ¢" 
                                                                                                               - Theraiyar 
           (Noi Nadal Noi Mudhal Nadal Part I) 
       Page No:270 
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1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
 
Naadi: 
"¿¡Ê ãý¨ÈÔõ ¿¡ÊÎí ¸¡¨Ä 
óÎÅ¢Ãø ¿¡Ê§Â ¸½¢ôÀ¡ý 
¿üÈÅ÷ìÌÕ¦ÅÉ ¿Å¢Ö Á¨È§Â". 
 
"ãýÈ¢¦Ä¡ý ÚÂ÷ó¾¨¾ ÓýÉ ÃÈ¢óÐ 
Óó¾¢Â¾¨É ¦Â¡Æ¢ò¾¢Î ÁÕó¾¢Î 
¾½¢Ôõ §¿¡Â¢ý ¾ó¾¢ÃÁ¢Ð§Å 
§À½¢ì ¸½¢ò¾¢Êý À¢ÈÅ¡ö À¢ý Ì½õ". 
   (Noi Nadal Noi Mudhal Nadal Part I) 
          Page No: 145 
 
From these stanzas it is very clearly understood that the diagnosis based on 
Naadi will bring out the best results. 
Pulse diagnosis is the confirmative diagnosis. Normally the pulse is 
recorded in an radial artery in the right hand for the male and left hand for the 
female by keeping the ring finger, the middle finger, and the index finger on it 
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after gently scrubbing the area. It is one unit in vatha as felt by the ring finger, and 
a half unit in pitha as felt by the middle finger and one fourth unit in kapha as felt 
by the index finger. The different disease could easily be diagnoses with the aid of 
the pulse. 
“¸¡¢Ó¸ÉÊ¨Â Å¡úò¾¢ ¨¸¾É¢ø ¿¡Ê À¡÷ì¸¢ø 
¦ÀÕÅ¢Ãø ÌÄò¾¢ü À¢Êò¾Ê ¿Î§Å ¦¾¡ð¼¡ø  
´Õ Å¢Ã§Ä¡Êø Å¡¾õ ‾Â÷ ¿ÎÅ¢ÃÄ¢ü À¢ò¾ó 
¾¢ÕÅ¢Ãø ãýÈ¢§Ä¡Êü §ºòÐÁ ¿¡ÊÂ¡§Á.” 
 
              -Agasthiyar Naadi shasthiram 
                                                (Noi Naadal Noi Mudhal Nadal Part I 
Page No 91) 
Å¡¾ ¿¡Ê: 
“Å¡¾¦ÁÛõ ¿¡ÊÂÐ §¾¡ýÈ¢ø  
  º£¾Áó¾¦Á¡Î ÅÂ¢Ú ¦À¡ÕÁø ¾¢Ãðº¢ Å¡ö× 
º£¾ÓÚí ¸¢Ã¡½¢ Á§¸¡¾Ãõ ¿£Ã¡¨Á 
  ¾¢ÃûÅ¡ö× Ý¨Ä ÅÄ¢¸ÎôÒò ¾£¨Ã 
¿£¾ÓÚí ¸¢ÕÁ¢ÌýÁõ «ñ¼Å¡¾õ 
   ¿¢¨ÄÔõ ¿£÷ì ¸¢¡¢îºÃí¸û ¾óÐ§Á¸õ 
§À¾¸Á¡ Ó¾ÃôÀ¢½¢ ãÄ§Ã¡¸õ  
   §Àº¦ÅÌ À¢½¢¸Ù§Á ¦À¡ÕÇ ¾¡§Á.” 
-º¾¸ ¿¡Ê 
                                                         §¿¡ö ¿¡¼ø §¿¡öÓ¾ø ¿¡¼ø ¾¢ÃðÎ.  
  À¡¸õ:1, Àì¸ ±ñ: 173 
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“Á¡¾÷ ¨¸À¢Êò¾ §À¡Ð Åó¾¢Îõ Å¡¾¿¡Ê 
¾£ÐÈ¦ÅÊòÐ À¡öóÐ º¢¾È¢§Â º¢ÄõÀ¢É¢ýÈ¡ü 
§À¨¾¾ý ÅÂ¢üÈ¢ý ‾û§Ç ¦ÀÕÌ Í§Ã¡½¢¾§Á ¾í¸¢  
Å¡¾¸û Àñ½ Á¡¾Å¢¼¡ö¸¡Äõ ÅÕò¾õ ¦ºöÔõ 
þÎô§À¡Î ¸ÎòÐ ¦¿¡óÐ þ¨¼Å¢¼¡ì Ìò¾Öñ¼¡ö 
¾Îò¾¢¼¡ ¸÷ôÀó¾ý¨É ¾í¸¢¼¡ Åñ½õ ¦ºöÔõ.” 
-À¾¢¦Éý º¢ò¾÷¸û ¿¡Ê º¡Š¾¢Ãõ 
 
“Á¡¾÷¨¸À¢Êò¾ §À¡¾Åó¾¢Îõ ¿¡Ê ãýÚõ 
§º¾Á¡Â¢üÚ ¿¢ýÈ§ºÃ§Å À¾¢óÐ ¿¢ü¸¢ø 
µ¾§Á Ý¾¸ò¾¢ø ´í¸¢Â Å¡ö§Å ¿¢ýÚ 
§À¨¾Â¡ö Å¡¨¾ÀýÉ¢ À¢½¢¸¨Ç Å¢¨ÇÅ¢ìÌó¾¡§É” 
- À¾¢¦Éý º¢ò¾÷¸û ¿¡Ê º¡Š¾¢Ãõ. 
 
ENVAGAI 
THERVU 
CHARACTER   IN SOOTHAGA VAAYU 
1.Naadi   Vatha naadi 
2.Naa   Colour  
 Coated  
 Taste  
Constipation is one of the 
symptoms of the soothagavaayu. 
Therefore tongue is coated and 
pale 
3.Niram Skin colour Hyper pigmentation in cubital 
fossa, armpits, neck, thigh, 
etc[acanthosis nigricans]  
4.Mozhi Articulation and 
speech 
No abnormality in speech. Sama 
oli 
5.Vizhi Niram (pallor, icterus) No abnormality 
6.Sparisam • Touch  
• Pain  
• Temperature  
Lower abdominal pain 
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7.Malam Niram- colour  
Irugal, Ilagal-
consistency 
Manam – odour  
Constipation  
8.Motthiram Niram - colour   
Manam-smell 
Nurai -forth 
Eadai-specific gravity 
Enjal - deposit   
 
No abnormality  
 
Neerkuri : 
“«ÕóÐÁ¡È¢¾Óõ «Å¢§Ã¡¾Á¾¡ö 
«·¸ø «Ä÷¾ø «¸¡Äçñ ¾Å¢÷ó¾Æü 
ÌüÈÇÅÕó¾¢ ‾Èí¸¢ ¨Å¸¨È 
¬Êì¸Äºò ¾¡Å¢§Â ¸¡Ð¦Àö 
¦¾¡ÕÓÜ÷ò¾ì ¸¨ÄìÌðÀÎ ¿£¡¢ý 
¿¢ÈìÌÈ¢ ¦¿öìÌÈ¢ ¿¢ÕÁ¢ò¾ø ¸¼§É.”  
  (Noi Naadal Noi Mudhal Nadal Part I 
                     Page No 282)  
This stanza explains the rules for the collection of urine for neerkuri 
and neikuri.  
 
Neikuri : 
“³ìÌÈ¢ ¦¸¡ÎÅ¼ Å¡É¢Æ ÄÁ¡ó§¾¡÷ 
¨¸ìÌÈ¢ ¦¾¡¢ò¾ ¿í¸¼×¨Çò Ð¾¢ò§¾ 
¦ÁöìÌÈ¢ ¿¢Èó¦¾¡½¢ Å¢Æ¢¿¡ þÕÁÂõ 
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¨¸ìÌÈ¢ ÓØÅàÅí ¸üÈ¡÷ ¾õÁ¢Ûõ  
¦À¡öìÌÈ¢ ¦ÁöìÌÈ¢ Ò¸Ö¦ÁÅ÷ìÌ 
¦¿öÌÈ¢Â¾¨É þó¿£É¢Âò Ð¨ÃôÀ¡õ.”  
   (Noi Naadal Noi Mudhal Nadal Part I 
Page No 297) 
 
The urine is kept on the kidney tray in sunlight, on a non windy condition, should 
be examined by dropping a drop of gingelly oil gently, with a stick. If the oil 
spreads like snake, it indicates Vatha, a ring indicates Pitha, and floats like a pearl 
in kapha. 
“«Ã¦ÅÉ ¿£ñ¼Ð Å¡¾ ¿£÷” 
In soothagavaayu when a drop of oil is put in the patient’s freshly 
collected urine the oil drop spread like a snake which indicates vatha neer. 
 
The eight stools of diagnosis are used not only for that purpose, but 
also to study the prognosis. The urine examination is widely used to study the 
prognosis. If the oil drop for the urine examination spreads in the shape of rice pot, 
a dwarf, betel leaf, horse, the prognosis is good. But if it spreads like a bird, dog, 
lion, pig, monkey, scorpion, cat, human being, the prognosis is bad. If the drop 
spreads rapidly the prognosis is bad. If the drop spreads slowly the prognosis is 
good and the disease is easily curable. 
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MODERN ASPECT 
FEMALE REPRODUCTIVE SYTEM: 
The main functions of female reproductive system are 
• Production of sex hormones 
• Production of functioning gamates [ova]  
• Support & protection of developing embryo 
The female reproductive system consists of internal and external genitalia. 
EXTERNAL GENETALIA 
• The external female genitalia are referred to as vulva. It consists of labia 
majora and labia minora, mons pubis, clitoris, opening of the urethra, 
vaginal vestibule, vestibular bulbs, and glands. 
• The vestibule is the space into which the vagina and urethra open. The 
urethra opens just anterior to the vagina.  
• The vestibule is bordered by a pair of thin, longitudinal skin folds called the 
labia minora. 
• Lateral to the labia minora two prominent rounded folds of skin called the 
labia majora. 
• The two labia majora unite anteriorly in an elevation of tissue over the 
pubic symphysis called the mons pubis. The lateral surface of the labia 
majora and the surface of the mons pubis are covered with coarse hair.  
• The medial surface of the labia majora are covered with numerous 
sebaceous and sweat glands. The space between the labia majora is called 
the pudendal cleft. 
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• A small erectile structure iscalled the clitoris is located in the anterior 
margin of the vestibule. The two labia minora unite over the clitoris to form 
a fold of skin called the prepuce. 
INTERNAL GENITALIA 
The internal reproductive organs situated in the pelvis between the bladder 
and rectum. They are held in space within the pelvis by a group of ligaments. The 
most conspicuous is the broad ligament which spreads out on both sides of the 
uterus and to which the ovaries and uterine tubes attach. 
The internal genitalia includes 
• VAGINA 
• UTERUS 
• FALLAPIAN TUBES 
• OVARIES 
VAGINA 
• The vagina is a canal that cervix (the lower part of uterus) to the outside of 
the body. It also is known as the birth canal. 
• It is a fibro muscular tube of about 10cm long extending from the uterus to 
outside of the body. 
• It is female organ of copulation and allows menstrual flow and child birth. 
In young females it is covered by a thin mucous membrane called hymen. 
UTERUS 
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• The uterus is a hollow, pear-shaped organ which is divided into parts 
namely Cervix, which is the lower part that opens into the vagina, and the 
main body of the uterus, called the corpus. 
• The uterine wall is composed of three layers, 
• Outer serous layer or perimetrium, 
• Middle muscular layer or myometrium,  
• Innermost endometrium. 
• The endometrium consists of simple columanar epithelial cells with 
underlying connective tissue layer. The superficial part of endometrium is 
sloughed down during menstruation. 
FALLAPIAN TUBES 
There are two uterine tubes also called uterine tubes or oviducts. One 
uterine tube is associated with each ovary. The uterine tubes extend from the 
ovaries to the uterus. They open pear the ovary to receive the oocyte and the 
opening is surrounded by long thin processes called fimbriae. As soon as oocyte is 
ovulated, it comes into contact with the surface of the fimbriae and the cilia on the 
fimbrial surface sweep the oocyte into the uterine tube. Fertilization usually occurs 
in the uterine tube near the ovary. 
OVARIES 
• The two ovaries are small oval shaped organs attached to ligaments that 
suspend them in the pelvic cavity and from the ligament of the uterus. 
• The suspensory ligament extends from each ovary to the lateral body wall 
and the ovarian ligament attaches the ovary to the uterus. The ovarian 
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vessels and nerves traverse the suspensory ligament and enter the ovary 
through the menovarium.  
• A layer of visceral peritoneum called tunica albuginea covers the ovary. 
The outer cortex of the ovary is made up of dense connective tissue 
containing ovarian follicles. Each of the ovarian follicles contains an oocyte 
the female germ cell. The inner medulla made of loose connective tissue is 
highly vascularised. 
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HORMONAL INTERACTIONS IN THE REPRODUCTIVE 
FUNCTIONS 
Neuroendocrinology with vast hormonal interactions is responsible 
for menstrual cycle and reproductive functions in women. A normal menstrual 
cycle depends on cyclical ovarian steroid secretions which in turn are controlled 
by the pituitary and the hypothalamus and to same extend by the thyroid and 
adrenal glands. It is therefore essential to understand the hypothalamic-pituitary-
ovarian axis in normal women. 
The following hormones play the major role, 
• Gonadotropin releasing hormone(GnRH)- hypothalamus  
• Follicle stimulating hormone(FSH)- anterior pituitary  
• Luteinising hormone(LH)- anterior pituitary  
• Oestrogen- ovary 
• Progesterone-ovary 
• Inhibin- ovary 
• Testosterone- ovary 
 
GONADOTROPIN RELESING HORMONE (GnRH) 
• GnRH is secreted by the hypothalamus which modulates the neural control 
of FSH and LH by the anterior pituitary. 
• GnRH is released in a pulsatile manner and the pulsatility and amplitude of 
its release varies with various phases of the menstrual cycle.  
• In preovulatory phase it pulses every 60mins but slows down in leuteal 
phase to one in 3 hours. GnRH is continuous in males but pulsatile in 
female in females. 
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• The hypothalamus is controlled by higher cortical centres especially 
temporal lobe. Emotional upsets stimulate or depress the H-P-O axis and 
disturb the menstrual cycle. 
 
ANTERIOR PITUITARY HORMONES  
FOLLICLE STIMULATING HORMONES (FSH): 
• FSH controls the ripening of the primordial follicles and in combination 
with the luteinizing hormone activates the secretion of oestrogen.  
• Its activity starts as menstruation is ceasing, reaches the peak by 7th day and 
then declines to disappear around 18th day. Another small peak occurs in 
premenstrual phase. 
• Low FSH causes defective follicluogenesis and short or defective corpus 
luteal phase. 
  
LUTEINIZING HORMONE: 
• In combination with FSH it activates the secretion of oestrogen, brings 
about maturation of the ovum and causes ovulation.  
• LH stimulates the completion of the reduction division of the oocyte. 
Following ovulation, it produces luteinisation of the granulose and the 
theca cells and initiates progesterone secretion. The LH surge precedes 
ovulation by 24 to 36 hours. 
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OESTROGEN: 
• The main sources of oestrogen are the theca end granulose cells of the 
graffian follicles and corpus luteum, while the adrenal cortex is the 
secondary source.   
• Its level increase 6 to 7 days before ovulation and reaches the peak 2 days 
before ovulation and then declines.  
• It increase uterine vascularise and regenerate the endometrium after 
menstruation and is responsible for the proliferative hyperplasia of the 
endometrium. 
 
PROGESTERONE: 
• The corpus luteum is the main source of progesterone. The level rises after 
ovulation and reaches peak at mid luteal phase. With the degeneration of 
the corpus luteum, its level falls and brings about menstruation.  
• In an anovulatory cycle, progesterone is absent or negligible amount and 
the menstruation is brought by the fall in oestrogen level. 
• If pregnancy occurs the corpus luteum continues to enlarge and secrete 
progesterone. The high level of the hormone prevents menstruation and 
leads to amenorrhoea of pregnancy. 
 
INHIBIN: 
• Inhibin is a peptide secreted by the graffin follicle and suppress pituitary 
FSH. In normal folliculogenesis FSH and LH initiate the secretion of 
oestrogen by the graffian follicles. Oestrogen is responsible for the 
secretion of inhibin in the graffian follicles, which in turn suppress FSH but 
stimulates LH. 
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• In poly cystic ovarian disease, there is increased secretion of inhibin. This 
causes a low FSH and LH secretion by pituitary resulting in anovulation. 
 
TESTOSTERONE: 
• The ovarian stromal cells secrete androgenic products, namely 
Testosterone, Dehydroepiandrosterone (DHEA) and Androstenedione.  
• Androstenedione gets converted to oestrogen in the peripheral fat. They 
increase in ovarian stroma is responsible for the rise in these hormones and 
development of hirsutism.   
FEMALE MENSTRUAL CYCLE    
• Menstruation (Greek Word, men - month) is monthly uterine bleeding 
outflowing through vagina onto vulva for 4-5 days every 28 days during 
reproductive life of a women from menarche to menopause. Menses are 
normal uterine function whereby endometrium prepares to receive 
pregnancy. 
Bleeding comes from oestrogen progesterone primed endometrium. 
Woman gets 13 menses in a year and around 400 menses in her reproductive life. 
The menstrual cycle of 28 days starts on day of onset of 
menstruation (day 1) and ends at day 28 on start of next mens. 
Menstruation signals that fertilization and embedding of fertilised 
ovum have not occurred on the preceding menstual cycle. Anovular menstruation 
is cyclical monthly bleeding from only oestrogen primed endometrium. This 
occurs for a few years after onset of menstruation (menarche) and before final 
cessation of menstruation (menopause). 
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 Day 1: 
o Menstruation 
 Estrogen—low 
 Progesterone—low 
 FSH—moderate 
 LH—low 
 Uterus— (functional layer of the uterus) are sloughing off 
 Day 7 
o Secondary Follicle Development 
 One of the primary follicles becomes secondary follicle. This 
is the only egg now being development. The secondary 
follicle has a space developing (calledantrum) 
 Estrogen—High 
 Progesterone—Low 
 FSH—low (because of negative feedback loop) 
 LH—low 
 Uterus—the functional starts to build up 
 Day 14 
o Ovulation 
 Estrogen—Very High 
 LH—Very High (because hypothalamus is releasing GnRh) 
 Progesterone—High 
 FSH—low 
 The secondary follicle is now Graphian follicle (it’s very big) 
 Remants in the ovary become the corpus luteum 
• Corpus Luteum—makes progesterone 
o Progesterone maintains uterine lining 
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 Day 28 
o Egg is not fertilized 
 Corpus Luteum degenerates 
 Corpus Luteum becomes Corpus Albacans (like scar tissue) 
• Corpus Albacans do not make progesterone 
 Estrogen---Decrease (women are more likely to be moody 
now) 
 Progesterone—Decrease after corpus luteum degenerates 
 Uterus—signals start of menstruation 
 
POLY CYSTIC OVARIAN SYNDROME 
HISTORY:  
 In 1935 –Stein & Leventhal first described poly cystic 
ovarian syndrome. 
 In late 1960 and early 1970 deranged hypothalamic- pituitary 
-axis is described.  
 In 1980 late complications related to insulin resistance. 
 By 1980 the use of ultra sound scans, the characterised poly 
cystic appearance was recognized. 
  PREVALENCE: 
 75% of hirsute women with normal menses but anovulatory 
cycles. 
 40% of hirsute women with normal ovulatory cycles(mild 
form of Pcos) 
 20% of normal women have mild form of pcos.  
 4-7% 0f female in reproductive age has clinically evident 
pcos. 
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NOMENCLATURE:  
 Poly cystic ovary disease 
 Stein- Leventhal syndrome 
 Functional ovarian hyperandrogenism 
 Ovarian hyperthecosis 
 Sclero cystic ovary syndrome 
DEFINITION: 
The two definitions are commonly used,  
Definition 1: (1990) if a female patient has all the following, 
• Oligomenorrhoea 
• Signs of androgen excess 
• Other entities causing poly cystic ovaries are excluded 
 Definition 2: (2003) Rotterdam indicated pcos to be present if 2 out of 3 
criteria are met 
• Oligomenorrhoea 
• Anovulation  
• Poly cystic ovaries(ultra sound) 
• Other endocrine disorders are excluded. 
 
 AETIO PATHOGENESIS: 
There is disagreement and uncertainty as to what causes polycystic 
ovarian disease. Polycystic ovaries and polycystic ovary syndrome have been 
associated with one or more of these factors:  
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• Genetic predisposition.  
• Insulin resistance or hyperinsulinism (high blood levels of 
insulin).  
• Obesity.  
• Hyperandrogenism (excessive production of male hormones).  
• Abnormality of the hypothalamic-pituitary-gonadal axis 
(organ/hormonal disorder).  
• Environmental chemical pollution (hormonal disruptors)  
• Food adulterantion (excitatory amino acids, for example)  
• Chronic inflammation.  
Some of these causal factors may also be consequences of polycystic 
ovary disease. In other words, we have an amazingly complex network of 
interacting variables, each of which influences the other. Polycystic ovarian 
syndrome is not a simple disease with a single cause.  
PATHOGENISIS: 
• Over secretion of LHRH in hypothalamus causes increased secretion 
of the LH by the pituitary gland. The LH stimulates the ovarian 
stroma to secrete androstenedine which is converted to estrone in the 
fatty tissue. 
• The excess of estrone suppress the secretion of FSH and sensitizes 
the pituitary to LHRH, increasing the secretion of LH. 
• Inhibin F – a poly peptide secreted by the granulosa cells in the 
ovaries may reduce further the secretion of FSH. 
• The increase in the ratio of LH and FSH in the plasma is the 
characterised of pcod. The imbalances between the LH &FSH 
become self perpetuating. 
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• Androstenedione is also converted to testosterone but the 
concentration of testosterone in the plasma usually remains in high 
normal range. 
• The secretion of oestrogen by ovaries is reduced. 
• Obesity common in the patients with the endocrine imbalance 
because the adipose tissue possesses aromatase enzyme that converts 
androstenedione to estrone and testosterone to estradiol. 
• Excess of adipose tissue creates both excess androgens (responsible 
for hirsutism and virilisation) and excess oestrogen (inhibits FSH by 
negative feedback). 
• Hyper insulinaemia increase GnRH pulse frequency, LH over FSH 
dominance and increased ovarian androgen production. The elevated 
insulin levels also act on liver to inhibit production of sex hormone 
binding (SHBH) which leads to an increase in free testosterone. 
• Insulin resistance is a common finding among patients of normal 
weight as well as those overweight patients. 
• Insulin like growth factor 1 binding protein is reduced which leads to 
increased circulating insulin like growth factor 1 enhancing ovarian 
androgen production. 
• Some women may also have increased adrenal androgenic 
production. 
• All these leads to the decreased follicular maturation and 
anovulation which is the most common cause of infertility. 
SIGNS AND SYMPTOMS: 
    Polycystic ovarian syndrome presents a complex and baffling 
array of symptoms, consisting of some combination of the following symptoms 
that vary with each individual:  
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• Multiple ovarian cysts  
• Irregular or absent menses  
• Infertility  
• Acne  
• Obesity or inability to lose weight  
• Excessive body or facial hair (hirsutism)  
• Insulin resistance and possibly diabetes  
• Thinning of scalp hair 
• Velvety, hyperpigmented skin folds (acanthosis nigricans)  
• High blood pressure  
• Polycystic ovaries that is 2-5 times larger than healthy 
ovaries.  
• Sleep apnea  
• Disordered immune system  
• Mood disorders, including anxiety and depression  
• Appetite disorder  
• High blood fats (cholesterol and triglycerides)  
• Increased probability of cardiovascular disease or diabetes  
• Multiple hormone imbalances, commonly including:  
• Androgens (testosterone)  
• Estrogens 
• progesterone  
•  Prolactin  
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• FSH (follicle stimulating hormone)  
• LH (luteinizing hormone)  
• Cortisol  
• Insulin  
• Thyroid hormone 
 
COMPLICATIONS 
  Women with PCOS are at risk for the following, 
• Endomentrial hyperplasia and endometrial carcinoma 
  Possibliy due to over accumulation of the uterine lining and also lack 
of progesterone resulting in prolonged stimulation of uterine cells by estrogen and 
also may be due to obesity, hyper insulinaemia and hyper androgenism. 
• Hyper Insulinaemia 
  High fastingf and post prandial insulin level 
  Peripheral insulin resistance. 
• Type 2 diabetes mellitus 
• Dyslipidaemia 
  Disorder of  lipid metabolism,cholesterol and triglycerides.PCOS 
patients show decreased removal of  atherosclerosis inducing remnants. 
• Cerebro and cardio vascular diseases 
 Hypertension 
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 Endothelial dysfunction and impaired fibrinolysis (Circulating 
plasminogen activating factors levels) associated with the risk for 
vascular lesions like ischaemic heart disease and stroke. 
• Infertility 
  The chronic elevation of insulin levels and enhanced ovarian 
sensitivity to insulin combined with elevated LH concentration results in 
ovarianthecal hyperplasia, increased androgen secretion arrested follicular 
development anovulation  resulting  in menstrual disturbance and infertility. 
• Miscarriage 
  This may be due to lack of progestertrone 
• Acanthosis nigricans 
  Patches of darkened skin under the arms, in the groin area and on the 
back of the neck 
• Auto immune thyroiditis 
DIAGNOSIS: 
The diagnosis is made using the Rotterdam criteria, even when the 
syndrome is associated with a wide range of symptoms. 
STANDARED DIAGNOSTIC ASSESSMENTS: 
History taking: 
• Specifically for menstrual pattern, obesity, hirsutism and absence of 
breast discharge. 
• These four questions can diagnosis PCOS with a sensitivity of 
77.1% and specificity of 93.8%. 
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Gynaecological ultrasonography:  
• Looking for peripherally placed small ovarian follicles of size 5-7 
mm giving the appearance of string of pearls and increased size of 
the ovaries that is 1.5 to 3 times larger than the normal.  
 
Laparoscopic examination: 
• This reveals a thickened smooth pearl white outer surface of the 
ovary.  
COMMEN ASSESSMENT FOR ASSOCIATED CONDITIONS OR 
RISKS: 
• Fasting blood glucose and lipid profile. 
• 2 hour oral glucose tolerance test (GTT) in patients with risk factor 
(obesity, family history, H/o gestational diabetes) and may indicate 
impaired GTT in 15%- 30% women with PCOS. 
• Frank diabetes can be seen in 65%-68% of women with this condition.  
• Insulin resistance can be observed in both normal weight and overweight 
patients. 
• Fasting insulin level to predict the response to medication. 
 
THE EXCLUSION OF OTHER DISORDERS: 
• Prolactin to rule out hyper prolactinaemia. 
• TSH to rule out Hypothyroidism 
• 17-hydroxy progesterone to rule out congenital Adrenal hyperplasia. 
DIFFERENTIAL DIAGNOSIS: 
Other causes of irregular or absent menstruation and hirsutism are, 
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• Adrenal hyperplasia 
• Cushing’s syndrome 
• Hyper prolactinaemia 
• Androgen secreting neoplasm’s 
• Other pituitary and adrenal disorder 
• Other insulin resistant situations such as acromegaly. 
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TRIAL MEDICINES 
 
PURGATION : 
AGASTHIYAR KUZHAMBU-100mg with Milagu (Piper Nigram)  
and Chukku (Zingiber officinale) mixed powder at early morning for 3 days. 
Reference book: Siddha vaithiya thiratu, Page No 172 
TRIAL DRUG- 1: SOOTHAGATHAI UDAIKKUM KASAYAM 
Reference book: Sigicha rathana deebam, Page No 96 
§¾¨ÅÂ¡É ºÃìÌ¸û: 
• ´Áõ 
• º¾Ìô¨À 
• ãí¸¢Ä¢¨Ä 
• Á¡Å¢Ä¢í¸õ Àð¨¼ 
• ÀÈí¸¢î ºì¨¸ 
• ÍìÌ 
• ¾¢ôÀ¢Ä¢ 
• º¢ò¾¢Ã ãÄ§Å÷ 
• º¢ò¾¢Ã ãÄ§Å÷ Àð¨¼ 
• ¸Õïº£Ã¸õ 
Å¨¸ìÌ ´Õ ÅÃ¡¸¦É¨¼ 
 
¦ºöÓ¨È: 
§Áü¸ñ¼ ºÃìÌ¸¨Ç ¿Úì¸¢ 1/2 ÀÊ ºÄõ Å¢ðÎ «¨Ã¸¡øÀÊÂ¡¸ 
Íñ¼ì¸¡öî¸¢ì ¦¸¡ûÇ×õ. 
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«Ç×: 
150ml ¾¢Éõ ´Õ §Å¨Ç, 3 ¿¡ð¸û 
¾£Õõ À¢½¢: 
Á¡¾Å¢ÄìÌ ´Øí¸¡¸ ÅÕõ 
TRIAL DRUG-2: MAENI LAVANA CHOORANAM 
Reference book:Kannusamy parambarai vaithiyam, Page No 116 
§¾¨ÅÂ¡É ºÃìÌ¸û: 
ÍìÌ - 10 ÀÄõ 
þóÐôÒ - 10 ÀÄõ 
§º¡üÚôÒ - 10 ÀÄõ 
¦ÀÕí¸¡Âõ - 5 ÀÄõ 
µÁõ - 10 ÀÄõ 
¦ºöÓ¨È: 
´Õ ºðÊÂ¢ø ¦ÀÕïÍìÌ ÐñÎ¸¨Ç §À¡ðÎ Á¢¾ì¸ Ìô¨À§ÁÉ¢ 
þ¨Äîº¡Ú Å¢ðÎ °È ¨Åì¸×õ. ÁÚ¿¡û ¸¡¨ÄÂ¢ø ÓýÅ¢ð¼ º¡ü¨È 
ÅÊòÐÅ¢ðÎ Óý§À¡ø Ò¾¢Â Ìô¨À§ÁÉ¢ þ¨Äîº¡Ú ãú¸Å¢ðÎ ¨Åì¸×õ. 
þùÅ¡Ú 18 ¿¡û ¦ºöÐ 19ÅÐ ¿¡û «îÍìÌò ÐñÎ¸¨Ç þÃñÎ, ãýÚ ¿¡û 
¿¢ÆÄ¢ø ¸¡Â¨ÅòÐô À¢ýÒ ¦ÅÂ¢Ä¢ø þÃñ¦¼¡Õ ¿¡û ¸¡ÂÅ¢ðÎô 
Àò¾¢ÃôÀÎòÐ¸.  
«ôÀ¡ø §º¡üÚô¨ÀÔõ þóÐô¨ÀÔõ ¸øÅò¾¢ø §À¡ðÎì Ìô¨À§ÁÉ¢ 
þ¨Äîº¡Ú Å¢ðÎ ÌÆõÒ À¾Á¡¸ «¨ÃòÐ ¨ÅòÐì ¦¸¡ûÇ×õ. ´Õ 
Ì¨¼ì¸õÀ¢¨Â ´ÕÒÈõ °º¢§À¡ø §¾¡öòÐ «¾É¢ø þÃñÎ ãýÚ 
ÍìÌòÐñÎ¸¨Ç Ìò¾¢ «ÅüÈ¢üÌ ÓýÒ º¢ò¾ôÀÎò¾¢Â ‾ôÒì ÌÆõ¨Àò 
¾ØõÀô âº¢ ¸¡¢¦¿ÕôÀÉÄ¢ø Å¡ð¼×õ. ‾ôÒ º¢Îº¢ÎôÒì ¸¡Ïõ§À¡Ð ÍìÌò 
ÐñÎ¸¨Çì ¸õÀ¢¨Â Å¢ðÎ ¿£ì¸¢ ´ÕÒÈõ ¨ÅòÐì ¦¸¡û¸.  
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þôÀÊ§Â ±øÄ¡î ÍìÌÐñÎ¸¨ÇÔõ ¸õÀ¢Â¢ø ¦ºÕ¸¢ §Á§Ä ¾ØõÀ 
‾ôÒì ÌÆõ¨À «ôÀ¢ ¦¿ÕôÀ¢ø Å¡ðÊ ±ÎòÐì ¦¸¡ûÇ×õ. þ¾üÌ §Áø 
µÁò¨¾ ¦À¡ý§ÁÉ¢Â¡¸ þÇïÝðÊø ÅÚòÐô ¦ÀÕí¸¡Âò¨¾ Å¡º¨É 
¸¢ÇõÀî ÍðÎ ±ÎòÐõ ¬ÈÅ¢ðÎ Óý ÓÊò¾ ÍìÌÐñÎ¸Ù¼ý ÜðÊ þÊòÐ 
º£¨ÄÂ¢ø «¡¢óÐ ¨ÅòÐì ¦¸¡û¸. 
«Ç×: 
• ¾¢¡¢¸ÊôÀ¢ÃÁ¡½õ - 1 ¸¢Ã¡õ [¸¡¨Ä, Á¡¨Ä] 
• º¢È¢Ð ¾ñ½£÷ Å¢Øí¸ ¦ºö¸ 
¾£ÕõÀ¢½¢¸û: 
• ±ò¾¨¸Â ¦¸¡ÊÂ ÅÂ¢üÚÅÄ¢ 
• ÌýÁõ 
• Ý¾¸Å¡Ô 
‾½×: 
 ±Ç¢¾¢ø ƒ£Ã½¢ì¸ÜÊÂ þÄÌ §À¡ƒÉõ, §Á¡÷º¡¾õ 
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LITERATURE REVIEW OF TRIAL MEDICINES 
PROPERTIES OF MEDICINES: 
The drugs used in siddha medicine were identified by five 
properties. They are Suvai (Taste), Gunam(Character), Veeriyam(Potency), 
Pirivu(Class), Mahimai(Action). All these five properties are based on the 
elements (Panchaboothas) that are present in that drug. 
SUVAI: 
The basic taste are six namely Inippu(sweet), Pulippu(sour), 
Uppu(saline), Kaippu(bitter), Karppu(pungent), Thuvarppu(astringent). Each taste 
is the combination of any two boothas of the panja boothas. 
GUNAM: 
Every drug has few of the following ten pairs of gunas based on the 
panjaboothas present in the drug. The paired gunas are, 
Heavy & light, Cold & hot, Oily & dry, Mild & keen, Compact& 
mobile, Soft& hard,  
Clean& slimy, Smooth& rough, Minute & gross, Solid &liquid.  
VEERIYAM: 
Veeriya of a drug is classified into two, namely heat (veppam) and 
cold (Thappam) based on the presence of the bootha fire in that drug. The drugs 
which have predominant fire bootha usually have the salt, sour, punjent tastes. So, 
the drugs with these tastes are hot and vehement. Others are cold and slow in 
action. 
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PIRIVU: 
A class of a drug is based on the taste of the drug after the 
metabolism of the particular drug acted upon by the digestive fire. It is after-taste 
which either nourishes a particular physical and life constituents or destroys them. 
The sweet and the saline substance after metabolism become sweet. The sour is 
sour, while the astringent, punjent, and bitter become punjent. 
MAHIMAI: 
Every drug has got a specific action which is independent of the 
above four features, and that individual action is called mahimai. 
 
CONCEPTS OF NATPU (synergetic) AND PAGAI (antagonist)  
CHARAKKU: 
When compound medicines are prepared, the physician should know about the 
group of drugs which should be added together. This also helps in the process of 
purification of raw drugs. Two drugs which have a combined, synergetic action is 
a natpu charakku, and two drugs which have conflicting properties is a pagai 
charkku. This is also based on the boothas that are present in the drug. 
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TRIAL DRUG: 1 SOOTHAGATHAI UDAIKKUM 
KASAYAM 
INGREDIENTS: 
OOMAM 
CHATHAKUPPAI 
CHUKKU 
THIPPILI 
KARUNJEERAGAM 
SITHIRA MOOLA VAER 
SITHIRA MOOLA VAERPATTAI 
PARANGI SAKKAI 
MAAVILANGA PATTAI 
MOONGILILAI 
PROPERTIES 
OOMAM 
BOT NAME: Carum Capticum 
FAMILY : Apiaceae 
SUVAI : Karppu 
THANMAI : Veppam 
PIRIVU : Karppu 
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PART : Dried Fruits 
ACTIONS and USES : 
• Emmenagogue 
• Laxative 
• Anti inflammatory 
• Carminative 
• Anti Spasmodic 
• Anti-diuretic 
• Hypotensive 
• Abdominal Pain 
• Abdominal Tumours 
 
CHATHAKUPPAI 
BOT. NAME: Anethum graveolens  
FAMILY: umbelliferae 
SUVAI: Inippu, karppu 
THANMAI: veppam 
PIRIVU: karppu 
PART: Seeds 
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“Å¡¾¦Á¡Î Ý¾¢¸¡ Å¡¾õ º¢ÃÍ §¿¡ö 
§Á¡Ð¦ºÅ¢ §¿¡ö¸À §¿¡öãÎÍÃõ-µÐ¸¢ýÈ 
ãÄì ¸ÎôÒ Ó¾¢÷À¢Éºõ §À¡Ìõ 
»¡Äî º¾Ìô¨À ¿¡Î.” 
-Gunapaadam-moligai vaguppu.  
Page no:422 
ACTIONS AND USES: 
• Anti-spasmodic  
• Emmenogogue 
• Anti Inflammatory 
• Cardiotonic 
• Expectorant 
• Galactogogue 
• Amenorrhoea 
• Dysmenorrhoea 
• Pain in abdomen 
CHUKKU 
BOT. NAME: Zingiber officinale 
FAMILY: Zingiberaceae 
SUVAI: Kerppu 
THANMAI: veppam 
PIRIVU: karppu 
PART: Rhizome  
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ACTIONS AND USES: 
• Carminative  
• Laxative 
• Anti vaatha 
• Anti Inflammatory 
• Anodyne 
• Cholesterol lowering 
• Hypoglycaemic 
 
THIPPILI 
BOT. NAME: Piper longam 
FAMILY: Piperaceae 
SUVAI: Karppu, kaippu 
THANMAI: veppam 
PIRIVU: karppu 
PART: Dried fruits   
ACTIONS AND USES: 
• Carminative  
• Laxative 
• Anti Inflammatory 
• Expectorant 
• Aphrodisiac 
• Anti-oxidant 
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KARUNJEERAGAM 
BOT. NAME: Nigella sativa 
FAMILY: Ranunculaceae 
SUVAI: kaippu  
THANMAI: veppam 
PIRIVU: karppu 
PART: Seeds  
ACTIONS AND USES:  
• Emmenagogue 
• Anti-spasmodic 
• Anti-tumour 
• Carminative 
• Anthelmintic 
• Diuretic 
• Anti-oxidant 
• Analgesic 
• Galactogogue 
• Hypotensive 
 
SITHIRAMOOLA VAER & VAERPATTAI 
BOT. NAME: Plumbago zeylanica 
FAMILY: Plumbaginaceae 
SUVAI: karppu,  
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THANMAI: veppam 
PIRIVU: karppu 
PART: Root & Root bark 
ACTIONS AND USES: 
• Stimulate CNS 
• Skin disease 
• Gonorrhoea 
• Regulate menstrual disorder 
• Syphilis 
• Tuberculosis 
• Rheumatic pain 
 
PARANGI SAKKAI  
BOT NAME : Smilax China 
FAMILY :Lilliaceae 
SUVAI : Enippu 
THANMAI : Thatpam 
PIRIVU : Enippu 
PART : Pattai 
 
ACTIONS AND USES : 
• Anti Vadha 
• Anti Syphilitic 
• Anti inflammatory 
• Aphrodisac 
• Laxative 
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• Anodyne 
• Neuralgia 
  
MAAVILANGA PATTAI  
BOT NAME : Crataeva Magna 
FAMILY : Ranunculaceae  
SUVAI : Kaippu 
THANMAI : Veppam 
PIRIVU : Karppu 
PART : Pattai 
 
ACTIONS AND USES : 
• Anti Vadha 
• Anti inflammatory 
• Laxative 
• Carminative 
• Anthelmintic 
• Diuretic 
• Renal Calculai 
 
MOONGILILAI 
BOT NAME : Bambusa Arundinaceae 
FAMILY : Poaceae  
SUVAI : Thuvarppu 
THANMAI : Veppam 
PIRIVU : Karpu 
PART : Leaf 
GUNAM : 
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“Ý¾¸ Å¡öÅ¢ÉÐ §º¡½¢¾ó¾í ¸¡ÐÅÕ  
Á¡§¾! ÍÃó¾½¢Ôõ Å¡¾õ§À¡õâ-â¾Ã§Áø 
´í¸¢ ÅÇ÷ó¾¢¨ÆÔ §Á¡í¸¦ÄÛ ãí¸¢ÖìÌ 
Å¡íÌïÍ Å¡ºõ§À¡õ Å¡úòÐ. ”  
                        -Agasthiyar Gunavagadam 
                                            Gunapadamooligai Page No 783 
ACTIONS AND USES : 
• Emmenagaogue 
• Anti Pitha 
• Anthelmintic 
• Antispasmodin 
• Amenorrhoea 
• Dysmenorrhoea 
• Gonorrhoea 
• Lumbago 
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TRIAL DRUG-2: MAENI LAVANA CHOORANAM 
CHUKKU 
BOT. NAME: Zingiber officinale 
FAMILY: Zingiberaceae 
SUVAI: Kerppu 
THANMAI: veppam 
PIRIVU: karppu 
PART: Rhizome  
ACTIONS AND USES: 
• Carminative  
• Laxative 
• Anti vaadha 
• Anti Inflammatory 
• Anodyne 
• Cholesterol lowering 
• Hypoglycaemic 
 
OOMAM 
BOT NAME: Carum Capticum 
FAMILY : Apiaceae 
SUVAI : Karppu 
THANMAI : Veppam 
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PIRIVU : Karppu 
PART : Dried Fruits 
ACTIONS and USES : 
• Emmenagogue 
• Laxative 
• Anti inflammatory 
• Carminative 
• Anti Spasmodic 
• Anti-diuretic 
• Hypotensive 
• Abdominal Pain 
• Abdominal Tumours 
 
PERUNGAYAM 
BOT NAME: Ferrula asafetida 
FAMILY : Apiaceae 
SUVAI : Kaippu 
THANMAI : Veppam 
PIRIVU : Karppu 
PART : Oleo gum resin 
GUNAM: 
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“‾óÐ ¦¸÷ôÀó¾¢ý Å¢ò¾¢Ãï Ý¨ÄîÝ÷ 
‾¾¢Ãôâîº¢ º¢§ÄòÐÁòÐÚõ ÅÄ¢ 
Åóò¦Áöì¸Îô §À¡ÊÉÅ ÓüÚ§Á 
Á¡Ô¿¡Ú¿ó ¸¡Â¡í ¸¢¨¼ì¸¢§É.” 
     -Gunapadam Mooligai 
          Page No 710  
ACTIONS and USES : 
• Emmenagaogue 
• Anti Vadha 
• Anti Spasmodic 
• Laxative 
• Anti inflammatory 
• Carminative 
• Anthelmintic 
• Diuretic 
• Anti Diabetic 
• Anti Coagulant 
• Nervinetonic 
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INDHUPPU 
Other Name: Rock Salt or Nacl impura  
ACTIONS and USES : 
• Carminative 
• Emetic 
• Laxative 
• Cathartic 
• Abdominal disorders 
SOTRUPPU 
Other Name: Table Salt or Nacl 
ACTIONS and USES : 
• Laxative 
• Emetic 
• Anti Septic 
• Anthelmintic 
• Anti periodic 
• Prevent Glandular enlargement 
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KUPPAIMAENI 
BOT NAME: Acalupha Indica 
FAMILY : Euphorbiaceae 
SUVAI : Kaippu,Karppu 
THANMAI : Veppam 
PIRIVU : Karppu 
PART : Leaf 
ACTIONS and USES : 
• Emmenagaogue 
• Anthelmintic 
• Diuretic 
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MATERIALS AND METHODS 
(PROTOCOL) 
STUDY DESIGN: 
The clinical open trial on Soothaga vayu was conducted at the OPD section 
of POST GRADUATE – POTHU MARUTHUVAM department attached to 
ARIGNAR ANNA HOSPITAL OF INDIAN MEDICINE, CHENNAI-106, during 
the period 2011-2013. 
SAMPLE SIZE: 
20 Female patients in the age group 15-35 
SELECTION CRITERIA: 
Patients with the following criteria are included in the study. 
• Irregular menstruation 
• Amenorrhoea 
• Oligomenorrhoea 
• Dysmenorrhoea 
• Infertility 
• Constipation 
• Poly cystic ovary in ultra sound 
EXCLUSION CRITERIA: 
Patients with following criteria are excluded from the study, 
• Hypothyroidism 
• Peptic ulcer 
• Diabetes mellitus  
• Hypertension 
• Patients with positive Gravindex test. 
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WITHDRAWAL CRITERIA: 
• Patients who have not completed the trial period are withdrawn from the 
study. 
EVALUATION OF CLINICAL PARAMETERS: 
Patients are clinically evaluated by the following parameters, 
HISTROY TAKING 
Age, occupation, socio economic status, complains and its duration, 
menstrual history, marital history, family history, previous illness, personal 
habits were recorded in the case sheet for every patient at the time of first 
visit to the OP. 
INVESTIGATIONS: 
All patients were subjected to the laboratory investigations before and after 
the treatment. 
Blood: 
Complete haemogram, Bl. Sugar(F), Sr. cholesterol, TSH. 
Urine: 
Albumin, Sugar, Deposits, Gravindex test. 
 
 
USG: 
• Whole abdomen and pelvis. 
• Follicular study 
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CLINICAL DIAGNOSIS BASED ON SIDDHA SYSTEM: 
The parameters used to diagnosis soothaga vayu based on siddha 
system. 
• Poriyaal arithal 
• Pulanaal arithal 
• Vinaathal 
• Envagai thervugal 
• Uyir thaathukkal 
• Udal thathukkal 
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RESULT AND OBSERVATION 
A total number of 20 patients included in the study with signs and 
symptoms of soothaga vaayu were observed. The observations were tabulated 
regarding the following features. 
• AGE DISTRIBUTION 
• DISTRIBUTION OF KAALAM 
• OCCUPATION 
• SOCIO ECONOMIC STATUS 
• DIET HABITS 
• FAMILY HISTROY 
• MARITAL STATUS 
• DISTRIBUTION OF THINAI 
• PARUVAKAALAM 
• DISTRIBUTION OF VAATHAM 
• DISTRIBUTION OF PITHAM 
• DISTRIBUTION OF KABHAM 
• EZHU UDAL THATHUKKAL 
• ENVAGAI THERVUGAL 
• NEIKURI 
• CLINICAL MANIFESTATIONS 
• RESULT 
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AGE DISTRIBUTION 
Age (years) No. of cases Percentage 
15- 20 years 4 20% 
21- 25 years 10 50% 
26- 30 years 5 25% 
31- 35 years 1 5% 
 
 
 
Inference: 
20% of patients were in the age group 15-20, 50% of patients were 
in the age group of 21-25, 25% patients were in the age group 26-30, 5% of 
patients were in the age group 31- 35.  
 
 
 
 
 68  
DISTRIBUTION OF KAALAM 
 
Kaalam No. of cases Percentage 
Vaatha kaalam upto 33yrs and 4months 19 95% 
Pitha kaalam upto 34-66yrs and 8months 1 5% 
Kabha kaalam above 66yrs 0 0% 
 
 
 
Inference: 
95% of patients were in vatha kaalam and 5% of patients were in 
pitha kaalam. 
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OCCUPATION 
Work No. of cases Percentage 
Student 8 40% 
Working womens 4 20% 
House wife 8 40% 
 
 
 
Inference: 
40% patients were students and another 20% were working women 
and remaining 40% patients were house wife. 
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SOCIO ECONOMIC STATUS 
SOCIOECONOMIC STATUS 
 
No. of cases Percentage 
Low( below 10000/m) 3 15% 
Lower- middle(10000-20000/m) 7 35% 
Upper – Middle(20000 above) 10 50% 
 
 
 
Inference: 
50% 0f patients belonging to upper middle class, 35% of patients 
belonging to lower middle, 15% of patients belonging to below 10000/m. 
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DIET HABITS 
Diet No. of cases Percentage 
Vegetarian  3 15% 
Non - vegetarian 17 85% 
 
 
 
Inference: 
85% of patients were non- vegetarian and 15% of patients were 
vegetarian. 
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FAMILY HISTROY 
Family histroy No. of cases Percentage 
Present 3 15% 
Absent  17 85% 
  
 
 
Inference: 
Family history of soothaga vaayu was present in 15% of patients and 
absent in 85% of patients. 
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MARITAL STATUS 
Marital status No. of cases Percentage 
Married  8 40% 
Unmarried  12 60% 
 
 
 
Inference: 
 40% were married and 60% were unmarried.   
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DISTRIBUTION OF THINAI 
 
THINAI NO. OF CASES PERCENTAGE 
Kurinji  0 0% 
Mullai  0 0% 
Marutham  2 10% 
Neithal  18 90% 
Paalai  0 0% 
 
 
Inference: 
Neithal 90% , Marutham 10% 
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PARUVAKAALAM 
Kaalam No. of cases Percentage 
Kaar kaalam (Aug16-Oct15) 2 10% 
Koothir kaalam (Oct16-Dec15) 0 0% 
Munpani kaalam (Dec16-Feb15) 5 25% 
Pinpani kaalam (Feb16- Apr15) 3 15% 
Elavenil kaalam (Apr16-June15) 2 10% 
Muthuvenil (June16-Aug15) 8 40% 
 
 
Inference: 
10% patients were repoted in kaar kaalam, 0% patients were 
reported in koothir kaalam, 25% patients were reported in munpani kaalam, 15% 
patients were reported in pinpani kaalam, 10% patients were reported in elavenil 
kaalam and 40% patients were reported muthuvenil kaalam. 
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DISTRIBUTION OF VAATHAM 
Vaatham No. of cases Percentage 
Pranan  0 0% 
Abanan  20 100% 
Udanan  0 0% 
Vyanan  14 70% 
Samanan  5 25% 
Naagan  0 0% 
Koorman  0 0% 
Kirugaran  0 0% 
Devadhathan  0 0% 
Thananjeyan  - - 
 
 
Inference: 
 Abanan affected in 100%, vyanan affected 70%, samanan affected 
25%. 
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DISTRIBUTION OF PITHAM 
Pitham No. of cases Percentage 
Analagam  5 25% 
Ranjagam  15 75% 
Prasagam  0 0% 
Aalosagam  0 0% 
Saathagam  20 100% 
 
 
 
Inference: 
Analagam affected 25%, Ranjagam affected 75%, Prasagam affected 
0%, and Saathagam affected 100%. 
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DISTRIBUTION OF KABHAM 
Kabham No. of cases Percentage 
Avlambagam  0 0% 
Kilethagam  5 25% 
Pothagam  0 0% 
Tharpagam  0 0% 
Santhigam  14 70% 
 
 
 
Inference: 
Santhigam affected in 70% of cases and  kilethagam affected in 
25%. 
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EZHU UDAL THATHUKKAL 
Thathukkal No. of cases Percentage 
Saaram  20  100% 
Senneer  15 75% 
Oon  20 100% 
Kozhuppu  14 70% 
Enbu  14 70% 
Moolai  0 0% 
Suronitham  20 100% 
 
 
 
Inference: 
Saaram affected in 100% patients, Senneer affected in 75%, Oon 
affected in 45%, kozhuppu and enbu affected in 70%, Suronitham affected in 
100%. 
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ENVAGAI THERVUGAL 
THERVUGAL NO. OF CASES PERCENTAGE 
Naa 15 75% 
Niram  15 75% 
Mozhi  0 0% 
Vizhi  15 75% 
Sparisam  0 0% 
Malam  10 50% 
Moothiram  0 0% 
 
 
Inference: 
Naa affected in 75%,Niram affected in 75%, Vizhi affected in 75%, 
and  Malam affected in 50% of cases.  
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NAADI 
NAADI NO. OF CASES PERCENTAGE 
Pitha vaatham 13 65% 
Vaatha pitham 7 35% 
 
 
 
Inference: 
65% of cases had pitha vatham, 35% of cases had vaatha pitham. 
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NEIKURI 
NEIKURI NO. OF CASES PERCENTAGE 
Vatham (Snake like) 12 60% 
Pitham (Ring like) 7 35% 
Kabham (Pearl like)  1 5% 
 
 
Inference: 
60% of patients had Vatha neer neikuri, 35% of patients had pitha 
neer neikuri and 5% of patients had Kabha neer neikuri. 
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CLINICAL MANIFESTATIONS 
 
S.N
O 
SIGNS & 
SYMPTOMS 
Before Treatment After Treatment 
NO. 
OF 
CASES 
PERCENTAGE NO. OF 
CASES 
PERCENTAGE 
1. Irregular 
menstruation 
20 100% 2 10% 
2. Amenorrhoea  16 80% 2 10% 
3 oligomenorrhoea 13 65% 3 15% 
4. Dysmenorrhoea  14 75% 2 10% 
5. Constipation  10 50% 0 0% 
6. Infertility  4 20% 3 15% 
 
Inference: 
90% patients were relived from irregular menstruation, and the patients were 
relived from amenorrhoea are 70% oligomenorrhoea are 50%, dysmenorrhoea are 
65%, and all patents are relived from constipation, 5% are conceived. 
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RESULT 
Result No of cases Percentage 
Good 14 70% 
Fair 5 25% 
Poor 1 5% 
 
 
 
 
Inference: 
 Results obtained were 
• 70% cases good result 
• 25% cases fair result 
• 5% cases poor result 
 
 
 85  
DISCUSSION 
‘Soothaga vaayu’ which is compared with irregular menstruation due to 
poly cystic ovarian disease) is a common disease pertaining to the ovary. It is the 
most common cause for infertility.  Nowadays large population of women in their 
reproductive age are affected by soothaga vayu. But there is no complete and 
satisfactory relief from their symptoms by other system of medicine. 
Hence 20 female patients with soothaga vaayu were selected and the 
patients were examined based on both siddha and as well as modern aspects and 
all the necessary investigations were made during the history taking. 
Trial medicines administered were,  
1. SOOTHAGATHAI UDAIKKUM KASAYAM- 150ml OD at Morning 
for 3 days before food. 
2. MAENI LAVANA CHOORANAM - 1gm BD with Water after food.  
The above medicines were administrated for course of 3 months. 
All the 20 patients were clinically improved. Let me take out these results 
on each category to arrive a better conclusion. 
Age and kaalam distribution: 
In this study the incidence is more in the age group 21-25 years (50%), 26-
30 years (25%), 31-35 years (5%), 15-20 years (20%) are affected.  
Majority of the patients were reported in their vatha kaalam(95%). 
Soothaga vaayu which is resulting from the deranged vatha kutram has high 
incidence in the vatha kaalam. 
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Occupation: 
Student and house wife were equally affected (40%) and working women 
were affected (20%) 
Socio economic status: 
Women from upper socio economic status (50%) were more affected than 
the middle (35%) and lower economic status (15%) 
Diet habits: 
85% of patients were non vegetarian and only 15% were vegetarian. 
Family history: 
There is a family history of soothaga vaayu i.e. either the patients mother or 
sister is affected by the same problem. 15% of patients are having the 
family history. 
Marital status: 
40% of patients were married and 60% patients were unmarried. 
Distribution of Thinai: 
Most of the patients were reported during Neithal (90%) and Marutham 
(10%),. 
 
Paruvakaalam: 
 Most of the Patients were reported during the Muthuvenil (40%), Munpani 
Kaalam (25%) and in Pinpani Kaalam (15%) 
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Clinical manifestations of soothaga vaayu: 
All patients have irregular menstruation (100%), 80% have amenorrhoea, 
75% have dysmenorrhoea,  65% have oligomenorrhoea, 50% have 
constipation, 20% have infertility. 
Mukkutram: 
Vaatham:  
• In all the patients (100%) Abanan was affected resulting in irregular 
menstruation, constipation and some patient causes inability to 
conceive. 
• In 70% of patients Vyanan was affected producing low back pain 
and lower abdominal pain. 
• In 25% of patients Samanan was affected resulting in loss of 
appetite. 
 
Pitham: 
• In all 100% of patients Sathaga pitham was affected causing 
irregular menstruation, absence of menstruation and inability to 
conceive. 
• In 75% patients Ranjagam was affected causing pallor of lower 
eyelids, tongue. 
• Analagam was affected in 25% of patients causing loss of appetite. 
Kabham: 
• Santhigam was affected in 70% of patients resulting in low back 
pain and lower abdominal pain. 
 88  
• Kilethagam was affected in 25% of patients resulting in loss of 
appetite. 
• Therefore soothaga vayu results from the deranged vatham and 
pitham which affected the uterus resulting in irregular menstruation. 
Ezhu Udal thathukkal: 
• In 100% of patients Saaram and Suronitham affected causing 
tiredness and irregular menstruation. 
• Senner was affected in 75% of patients producing pallor and eyelids. 
• Oon was affected in 100% because of Cyst presence. 
• Kozhuppu was affected in 70% of patients resulting low back pain   
• Enbu was affected in 70% of patients resulting low back pain.  
Envagaii thervugal: 
• In 75% of patients Naa, Niram and Vizhli were affected depicting 
anaemic status of the patients. 
• Malam was affected in 50% due to constipation. 
Naadi: 
65% of patients had Pitha vatha naadi and 35% of patients had Vatha pitha 
naadi. 
Nei kuri: 
60% patients had Vatha neer, 35% patients had pitha neer and 5% had 
kabha neer. 
Ultra sound scan: 
USG-Pelvis was taken before treatment for all patients for confirmation of PCOD. 
18 patients had bilateral ploy cystic ovaries, 2 patients had unilateral poly cystic 
ovaries and follicular study was done for infertility. 
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Results after treatment: 
90% patients were relived from irregular menstruation, and the patients were 
relived from amenorrhoea are 70% oligomenorrhoea are 50%, dysmenorrhoea are 
65%, and all patents are relived from constipation, 5% are conceived. 
 Trial medicines: 
• Before administering the trial medicines all the patients were given 
Agasthiyar kulambu -100mg OD at early morning with Chukku and 
millagu mixed power neutralizes the vatha kutram.  
• Soothagathai Udaikkum Kasayam with Kaippu (Vali+Vinn) taste 
regulates body secretions, eliminates excess fat and also eliminates 
accumulated fluid in the tissue 
• Maeni Lavana Chooranam with Uppu (Neer+Thee) taste regulates  
Laxative and prevents the glandular enlargement                            
• Therefore the trial medicines will neutralizes the vatha kutram 
through Oppurai. 
Chemical Analysis: 
 Qulitative Analysis: 
  The sodium carbonate extract of the medicines were tested for Acid 
radicals, Basic radicals and miscellaneous compounds.  
 The results show the Soothagathai Udaikkum Kasayam contains Chloride, 
Calcium, Potassium, Reducing Sugar, Protein. 
Toxicological studies: 
• Acute and sub acute toxicity studies were conducted on experimental 
rats. 
• At the end of the toxicity studies the animals were sacrificed and the 
haematological parameters, liver function test, renal function test 
and histo pathology of vital organs like liver, lungs, spleen, and 
kidney were carried out.  
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• Their results show the Soothagathai Udaikkum Kasayam no signs of 
toxicity in female rats. 
Pharmacological studies: 
Soothagathai Udaikkum Kasayam in exhibited Ovulation induced activity 
in invitro method. 
Statistical analysis: 
• In both subjective and objective parameters were statistically 
significant. 
• Out of 20 cases 70% had good result, 25% had fair result and 5% 
had poor result. 
The statistical analysis of the results obtained from the clinical study was very 
much encouraging. 
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SUMMARY 
The results obtained from the studies are summarized below: 
♣ High incidence of cases was noted in the age group 21-25 years 
(50%) from upper middle socio economic group (50%) in their 
vatha kaalam (95%). 
♣ 85% of patients are Non vegetarian with 55% of patients with 
normal physical built. 
♣ Majority of patients belong to Neithal thinai (90%) and in 
Muthuvenil kaalam(40%). 
♣ In observing the Mukkutram, Abana vayu and sathaga pitham 
were affected in all patients indicating derangement of vatham 
and pitham. 
♣ In Ezhu udal thathukkal, Saaram and Suronitham are affected in 
all patients. 
♣ In Envagai thervugal Naa, Niram, Vizhi and Malam were 
affected in majority of patients. 
♣ Most of patients had pitha vatha naadi. 
♣ In soothaga vaayu all patients had irregular menstruation,75% 
had Dysmenorrhoea, 65% had Oligomenorrhoea and 50% 
patients had constipation. 
♣ The trial medicines having kaippu and Uppu taste neutralizes the 
deranged vayu and pitham based on oppurai. 
♣ The ingredients of the trial drugs have Emmenagogue, Anti-
vatha, Anti-pitha, Anti-Spasmodic, Anti-Tumour, 
Laxative,Carminative, hypolipidimic and Anti-diabetic action. 
♣ The pre clinical studies show that the medicines were safe with 
no signs of Toxicity and significant Ovulation Induced activity. 
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♣ The clinical trial shows that there is significant improvement in 
the clinical manifestations of Soothaga vaayu. 
♣ There is 75% relief from amenorrhoea, oligomenorrhoea, 
dysmenorrhoea constipation and 90% relief from irregular 
menstruation. 
♣  5% of patients conceived during the course of the treatment. 
♣ The pre clinical and clinical data’s were analysed statistically and 
observed that they are significant in relieving the symptoms with 
P value <0.05  
♣ Also the trial drugs are affordable to all the patients.   
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CONCLUSION 
♣ SOOTHAGA VAAYU(PCOS) is primarily due to the derangement of 
vatham and pitham. 
♣ The trial medicine Soothagathai Udaikkum Kasayam and Maeni Lavana 
Chooranam predominating with kaippu and karppu taste respectively 
neutralizes the vatham and pitham. 
♣ The trial medicines regularise the irregular menstruation, induces the 
ovulation and regulate hormonal imbalance. Therefore the trial medicines 
are beneficial in treating irregular menstruation and infertility due to 
anovulation. 
♣ From the pre-clinical, pharmacological studies it is evident that the trial 
medicines were significant Ovulation Induced activity. 
♣ Toxicity(Acute/Sub-Acute) study reliveded Soothagathai Udaikkum 
Kasayam had no signs of Toxicity 
♣ No contra indications were reported during the course of the treatment. 
♣ The trial medicines gave maximum relief from the symptoms of Soothaga 
vaayu. 
♣ The trial drugs are easily preparable and affordable. 
♣ Therefore I conclude that the Trial Medicines are best solution for 
SOOTHAGA VAAYU (PCOS). 
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ANNEXURE –I 
 
CHEMICAL ANALYSIS OF TRIAL MEDICINES 
 
Preparation of Sodium Carbonate extract: 2 gm of the sample is mixed  5 
gm of Sodium carbonate and taken in a 100 ml beaker and 20 ml of distilled water 
is added.  The solution is boiled for 10 minutes, cooled and then filtered.  The 
filtrate is called sodium carbonate extract. 
 
 
S.No. 
 
Experiment 
Drug1 
Observation  Inferance  
1 Test for Acid Radicals   
a. Test for Sulphate 
2 ml of the above prepared 
extract is taken in a test tube.  
To this add 2ml of 4% 
Ammonium oxalate solution. 
Absence of              
White  
Precipitate  
Absent 
b. 2ml of extract is added with 
2ml of dilute hydrochloric acid 
until the effervescence ceases 
off.  Then 2ml barium chloride 
solution is added. 
Absence of              
White  
Precipitate 
Absent 
2. Test for Chloride: 
2ml of extract is added with 
dilute nitric acid till the 
effervescence ceases.  Then 
2ml of silver nitrate solution is 
added. 
 
 white 
precipitate is 
obtained 
 
Present 
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3. Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate  solution and 2ml of 
concentrated nitric acid. 
Yellow 
Precipitate 
is obtained. 
Present 
4. Test for Carbonate: 
2ml of the extract is treated 
with 2ml of magnesium 
sulphate solution. 
Absence of 
white 
precipitate 
Absent 
5. Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated 
Hydrochloric acid 
Absence of 
Rotten egg 
smelling  
Absent 
6. Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid 
and viewed the test tube 
vertically down. 
Absence of 
reddish 
brown gas. 
Absent 
7. 
a. 
Test for Fluoride and oxalate 
2ml of the extract is added 
with 2ml of dilute acetic acid 
and 2ml of calcium chloride 
solution and heated.  
Absence of 
white 
precipitate 
Absent 
b. 5 drops of clear solution is 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate 
solution is added.  
Absence of 
KMNO4 
solution 
discolourisa
tion.  
Absent 
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8. Test for Nitrite 
3 drops of the extract is placed 
on a filter paper.  On that, 2 
drops a Acetic Acid and 2 
drops of Benzidine solution is 
placed. 
Absence of 
yellowish 
red colour  
Absent 
9. Test for Borate 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol 
(95%) and introduced into the 
blue flame. 
Absence of 
Green 
tinged flame 
Absent  
 
 
  
II. TEST FOR BASIC RADICALS  
10. Test for lead 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution 
Absence of 
Yellow 
precipitate 
Absent 
11a Test for Copper 
One pinch of substance is 
made into paste with 
concentrated Hydrochloric acid 
in a watch glass and introduced 
into the non luminous part of 
the flame. 
Absence of 
Bluish 
green 
coloured 
flame. 
Absent 
b. 2ml of the extract is added 
with excess of Ammonia 
solution 
Absence of 
deep blue 
Absent 
12. Test for Aluminium 
To the 2 ml of extract.  Sodium 
 Absence of     
White 
Absent  
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Hydroxide solution is added in 
drops to excess. 
precipitate. 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution is added. 
Absence of 
Blood red 
colour 
Absent  
b. To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution and 2 ml of 
concentrated Nitric Acid is 
added. 
Absence of 
Blood red 
colour 
Absent  
14. Test for Zinc 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of 
White 
precipitate 
Absent  
 15. Test for Calcium 
2 ml of the extract is added 
with 2 ml of 4% Ammonium 
Oxalate solution. 
White 
precipitate 
obtained.  
Present  
16. Test for Magnesium 
 2ml of extract, Sodium 
Hydroxide solution is added in 
drops to excess. 
 Absence of   
White 
precipitate. 
Absent 
17. Test for Ammonium 
 2 ml of extract few ml of 
Nessler’s Reagent and excess 
of Sodium Hydroxide solution 
are added. 
 
Absence of 
Reddish 
brown 
precipitate 
Absent 
18. Test for Potassium 
A pinch of substance is treated 
with 2 ml of Sodium Nitrite 
 Yellow 
precipitate 
Present 
 98  
solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
is obtained 
19. Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame. 
Absence of 
Yellow 
colour 
flame 
Absent  
 
 
  
20. Test for Mercury 
2 ml of the extract is 
treatedwith 2 ml of Sodium 
Hydroxide solution. 
Absence of 
yellow 
precipitate 
Absent  
21. Test for Arsenic 
2 ml of extract is treated with 2 
ml of silver Nitrate solution 
  Absence of                                                                                                                   
Yellow 
precipitate. 
Absent
22. Test for Starch 
2ml of extract is treated with 
weak iodine solution 
 Absence of 
Bluecolour 
Absent 
23. Test of reducing Sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added  10 drops of 
the extract and again boiled for 
2 minutes.  The colour changes 
are noted. 
Green 
colour is 
obtained. 
Present 
24. 
 Test of  the alkaliods               
2ml of the extract is treated 
with  2ml of potassium lodide 
Absence of 
red colour 
absent              
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solution 
25. 
 Test for Proteins               
2ml of the solution and 2ml of 
5% sodium hydroxide mixed 
and add 2 drops of copper 
sulphate solution. 
Violet 
colour 
formed 
Present              
 
 
 
 
RESULTS:   
 
The given sample contains. 
 
Drug : Soothagathai Udaikkum Kasayam 
 
Calcium, Chloride, potassium, reducing sugar and protein. 
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ANNEXURE –II 
ACUTE AND SUB ACUTE TOXICITY STUDY ON 
SOOTHAGATHAI UDAIKKUM KASAYAM IN RODENTS 
Animals  
 Mice of either sex weighing 25-30g and rats weighing 110-140g were 
obtained from the animal house of Vels University. The animals were used with 
the approval of the Institute animal ethics committee and obtained from Vels 
University, Chennai. They were fed with a balanced standard pellet diet and 
maintained under standard laboratory conditions, providing 24-280C temperature, 
standard light cycle (12 h light, 12 h dark) and water ad libitum. Animals were 
kept in cages with raised floors of wide mesh to prevent coprophagy. Animal 
welfare guidelines were observed during the maintenance period and 
experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The animals were acclimatized for one 
week under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Soothagathai Udaikkum Kasayam was 
carried out as per OECD Guidelines 425. As with other sequential test designs, 
care was taken to ensure that animals are available in the appropriate size and age 
range for the entire study. The test substance is administered in a single dose by 
gavage using a stomach tube or a suitable intubation cannula. The fasted body 
weight of each animal is determined and the dose is calculated according to the 
body weight. After the substance has been administered, food was withheld for a 
further 2 hours in mice. The animals were observed continuously for the first 4 h 
and then each hour for the next 24 h and at 6 hourly intervals for the following 48 
h after administering of the test drug, to observe any death or changes in general  
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behaviour and other physiological activities. Single animals are dosed in sequence 
usually at 48 h intervals. However, 
the time interval between dosing is determined by the onset, duration, and severity 
of toxic signs. Treatment of an animal at the next dose was delayed until one is 
confident of survival of the previously dosed animal.  
Observation of toxicity signs: General behavior, respiratory pattern, 
cardiovascular signs, motor activities, reflexes, change in skin and fur, mortality 
and the body weight changes were monitored daily. The time of onset, intensity, 
and duration of these signs, if any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex rats were 
divided into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were 
administered daily with the Soothagathai Udaikkum Kasayam (p.o.) for 28 days at 
a dose of 2.5, 5.0 and 10.0 ml/kg respectively. The animals were then observed 
daily for gross behavioural changes and any other signs of subacute toxicity. The 
weight of each rat was recorded on day 0 and weekly throughout the course of the 
study, food and water consumption per rat was calculated. At the end of the 28 
days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by 
cardiac puncture into heparinised tubes. The blood sample collected from each rat 
was centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used 
for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for 
hematological and blood chemical analyses were taken from retro orbital vein. 
Heparinized blood samples were taken for determining complete blood count 
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(white blood cell count, differential white blood cell count, platelet count, red 
blood cell count, hematocrit, and hemoglobin) by semiautomated hematology 
analyzer. The serum from non-heparinized blood was carefully collected for blood 
chemistry and enzyme analysis (glucose, creatinine, total protein, albumin, total 
and direct bilirubins, serum glutamate-oxaloacetate transaminase (SGOT), serum 
glutamate pyruvate transaminase (SGPT), and alkaline phosphatase (ALP)) were 
automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, 
sizes and colors of internal organs were evaluated. The Spleen, Testes, Pancrea, 
Lung, Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues 
were excised from all rats to visually detect gross lesions, and weighed to 
determine relative organs’ weights and preserved in 10% neutral formalin for 
histopathological assessment. The tissues were embedded in paraffin, and then 
sectioned, stained with haematoxylin and eosin and were examined 
microscopically. 
 
 
 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using one-
way analysis of variance (ANOVA) test using GraphPad Instat-V3 software. 
P<0.05 were considered significant. 
RESULTS 
1) All the animals from control and all the treated dose groups up to 10ml/kg 
survived throughout the dosing period of 28 days. 
2) No signs of major or significant intoxication were observed in animals from 
lower to higher dose groups during the dosing period of 28 days. 
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3) Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 4) Food 
consumption of control and treated animals was found to be comparable 
throughout the dosing period of 28days. 
5) Ophthalmoscopic examination, conducted prior to and at the end of dosing 
period on animals from control and all the treated dose groups did not reveal any 
abnormality. 
6) Haematological analysis conducted at the end of the dosing period on day 28, 
revealed no significant abnormalities attributable to the treatment. 
7) Biochemical analysis conducted at the end of the dosing period on day 28, 
revealed no remarkable abnormalities attributable to the treatment. 
8) Functional observation tests conducted at termination revealed no 
abnormalities. 
9) Urine analysis, conducted at the end of the dosing period in week 4, revealed no 
abnormality attributable to the treatment. 
10) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
11) Gross pathological examination did not reveal any abnormality. 
12) Histopathological examination did not reveal any abnormality. 
CONCLUSION 
 Based on these findings, no toxic effect was observed upto 10ml/kg of 
Soothagathai Udaikkum Kasayam via oral route over a period of 28 days. So, it 
can be concluded that the Soothagathai Udaikkum Kasayam can be prescribed for 
therapeutic use in human with the dosage recommendations of upto 10ml/kg. body 
weight p.o. 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
N
o 
Dos
e 
ml/k
g 
1 2 3 4 5 6 7 8 9 10 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
1. 5 + - - + - + - - - - - - - - - - - - - - 
2 10 + - - + - + - - - - - - - - - - - - + - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle 
Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 
15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. 
Mortality 
 
Table 2. Body weight of albino rats exposed to Soothagathai Udaikkum 
Kasayam for 28days. 
Dose 
(ml/kg/day
) 
1) Days 
1 7 14 21 28 
Control 110.45±4.0
5 
112.15±5.0
5 
114.48±4.2
0 
117.25±5.2
1 
120.40±5.9
2 
2.5 112.00±3.3
1 
117.20±5.1
0 
120.10±5.1
2 
124.26±5.0
5 
126.15±6.0
0 
5 115.24±4.4
4 
119.15±4.1
2 
123.08±4.1
0 
126.10±6.4
4 
129.30±5.1
4 
10 110.12±5.2
0 
112.24±5.3
0 
114.10±4.2
8 
118.25±5.1
2 
122.25±5.3
2 
Values are mean of 6 animals ± S.E.M. nsP>0.05 Vs control  
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Table 3. Food intake of albino rats exposed to Soothagathai Udaikkum 
Kasayam for 28days. 
Dose 
(ml/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 40.05±2.15 41.82±2.10 42.10±2.41 45.00±2.25 42.25±2.20 
2.5 41.24±2.71 42.23±2.62 43.24±2.62 42.05±2.19 44.21±2.02 
5 40.30±2.14 42.00±2.15 41.32±2.14 44.48±3.10 42.10±2.00 
10 42.12±2.25 41.21±2.32 42.18±2.52 42.10±2.00 44.04±2.14 
Values are mean of 6 animals ± S.E.M. nsP>0.05 Vs control 
Table 4. Water intake of male and female albino rats exposed to Soothagathai 
Udaikkum Kasayam for 28days. 
Dose 
(ml/kg/day) 
Days (ml/rat) 
1 7 14 21 28 
Control 52.10±2.28 51.00±3.13 52.28±3.18 50.72±3.16 50.20±3.12 
2.5 50.12±2.41 50.42±3.01 45.23±4.00 48.15±3.44 40.55±2.48 
5 44.70±2.18 40.12±3.82 40.87±3.32 44.14±2.19 44.10±3.24 
10 50.13±2.25 52.46±2.05 50.26±3.18 45.28±3.00 45.20±3.50 
Values are mean of 6 animals ± S.E.M. nsP>0.05 Vs control 
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Table 5. Hematological parameters after 28days treatment with Soothagathai 
Udaikkum Kasayam in rats. 
Parameter Control 2.5ml/kg 5ml/kg 10ml/kg 
Red blood 
cell (mm3) 
8.00±0.72 8.92±0.68 8.12±0.55 8.00±0.62 
HB (%) 15.12±0.42 15.10±0.49 15.52±0.42 15.02±0.41 
Leukocyte 
(x106/mL) 
10214±125.11 10288±110.24 10245±134.12 10264±119.42 
Platelets/ul 1242±30.14 1184±31.24 1132±30.22 1195±32.14 
MCV (gl) 54.44±5.12 53.88±4.72 55.00±4.27 54.12±4.80 
Neutrophil 5.46±2.81 5.42±3.27 5.18±3.96 5.14±3.47 
Lymphocyte 92.02±2.90 91.48±2.12 90.22±2.62 92.32±1.88 
Monocyte 2.42±0.23 2.20±0.28 2.28±0.20 2.22±0.24 
Eosinophil 1.00±0.00  1.00±0.22 1.00±0.11 1.00±0.11 
Basophil 0 0 0 0 
ESR(mm) 1±00 1±00 1±00 1±00 
PCV 44.20±2.62 45.24±2.18 45.10±2.02 45.14±2.22 
Values are mean of 6 animals ± S.E.M. nsP>0.05 Vs control 
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Table 6. Effect of treatment with Soothagathai Udaikkum Kasayam 
biochemical parameters. 
Dose (ml/kg) Control 2.5ml/kg 5ml/kg 10ml/kg 
Total Bilirubin 
(mg/dL) 
0.210±0.05 0.214±0.06 0.215±0.05 0.215±0.04 
Bilirubin direct 
(mg/dL) 
0.1±0.04 0.1±0.04 0.1±0.04 0.1±0.05 
Bilirubin 
indirect(mg/dL) 
0.1±00 0.1±00 0.1±00 0.1±00 
ALP (U/L) 380.42±10.10 378.22±10.22 376.82±10.04 390.12±11.21 
SGOT (U/L) 158.20±5.14 156.72±5.82 155.43±5.20 154.00±5.45 
SGPT(U/L) 45.82±2.30 44.58±2.28 45.00±2.18 46.02±2.92 
Total Protein(g/dl) 8.25±0.30 8.12±0.32 8.50±0.37 8.10±0.34 
Albumin(g/dl) 3.22±0.25 3.31±0.24 3.14±0.30 3.22±0.42 
Globulin(g/dl) 5.02±0.18 4.18±0.26* 4.18±0.21* 4.16±0.23* 
Values are mean of 6 animals ± S.E.M. *P<0.05; Vs Control 
Table-7 RFT 
Dose (ml/kg) Control 2.5ml/kg 5ml/kg 10ml/kg 
Urea(mg/dL) 55.22±2.60 55.30±2.56 55.42±2.42 55.48±2.36 
Creatinine 
(mg/dL) 
0.77±0.05 0.76±0.06 0.76±0.05 0.77±0.05 
Uric acid (mg/dL) 1.5±0.10 1.6±0.12 1.6±0.10 1.6±0.10 
Na m.mol 140.70±5.42 141.56±5.11 139.12±5.22 140.12±5.02 
K m.mol 20.22±2.78 19.87±2.08 20.40±2.36 20.10±2.42 
Cl m.mol 101.00±4.22 101.12±5.12 100.18±4.82 101.00±5.10 
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i)  
 
 
 
ii) Table-8. Lipid Profile 
Dose (ml/kg) Control 2.5ml/kg 5ml/kg 10ml/kg 
Total 
cholestrol(mg/dL) 
41.60±2.72 41.10±2.42 42.42±3.00 42.52±3.04 
HDL(mg/dL) 14.22±2.42 14.27±1.47 13.44±2.45 13.24±2.43 
LDL(mg/dL) 42.04±3.35 42.00±2.21 42.38±2.08 43.22±2.32 
VLDL(mg/dl) 15.30±2.25 15.25±2.30 15.02±2.64 15.16±2.20 
Triglycerides (mg/dl) 86.20±3.02 85.16±2.22 86.23±3.24 88.44±2.78 
TC/HDL ratio (g/dl) 3.86±0.34 3.82±0.38 3.72±0.32 3.66±0.30 
Blood glucose(mg/dl) 126.13±4.78 126.12±3.25 126.10±4.00 124.45±2.24 
Values are mean of 6 animals ± S.E.M. nsP>0.05 Vs control 
iii) Table-9 Urine Analysis 
b) Parameters Control 2.5ml/kg 5ml/kg 10ml/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly 
turbid 
Slightly 
cloudy 
Slightly 
turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
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i. Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-
cell/HPF 
2-
cells/HPF 
1-
cell/HPF 
RBCs Nil Nil 0-
1cells/HPF 
Nil 
Epithelial cells Nil 1-
cell/HPF 
Nil 1-
cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
 
Table 10. Effect of oral administration of Soothagathai Udaikkum Kasayam 
on organ weight 
Dose (ml/kg) Control 2.5ml/kg 5ml/kg 10ml/kg 
Liver (g) 5.28±0.16 5.30±0.15 4.98±0.12 5.10±0.14 
Heart (g) 0.62±0.04 0.62±0.04 0.61±0.04 0.60±0.04 
Lung (g) 1.45±0.06 1.44±0.19** 1.46±0.24** 1.42±0.15** 
Spleen (g) 0.66±0.05 0.66±0.04 0.65±0.04 0.65±0.05 
Ovary (g) 1.68±0.12 1.80±0.15 1.88±0.11* 1.95±0.10* 
Testes (g) 1.48±0.10 1.45±0.12 1.46±0.14 1.42±0.15 
Brain (g) 1.54±0.15 1.52±0.13 1.52±0.12 1.50±0.14 
Kidney (g) 0.72±0.04 0.71±0.04 0.70±0.05 0.71±0.05 
Stomach (g) 1.35±0.10 1.35±0.11 1.38±0.12 1.34±0.10 
Values are mean of 6 animals ± S.E.M. *P<0.05; **P<0.01. Vs Control 
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ANNEXURE –III 
EFFECT OF SOOTHAGATHAI UDAIKKUM KASAYAM ON 
OVULATION IN RATS 
INTRODUCTION 
 Infertility is one of the main problems seen in young couples. Due to cost 
and social problems, some couples seek traditional methods to treat their infertility 
before meeting with specialists. Since folk medicine plays an important role in 
individual and community primary health care, the use of herbal products are 
increasing in many countries. Polycystic ovary syndrome is characterized by 
anovulation and hyperandrogenism. Patients with this syndrome may complain of 
abnormal bleeding, infertility, obesity, excess hair growth, hair loss and acne. 
 In addition to the clinical and hormonal changes associated with this 
condition, vaginal ultrasound shows enlarged ovaries with an increased number of 
small (6-10mm) follicles around the periphery. While ultrasound reveals that 
polycystic appearing ovaries are commonly seen in up to 20% of women in the 
reproductive age range, Poly Cystic Ovary Syndrome is a estimated to affect about 
half as many or approximately 6-10% of women. The condition appears to have a 
genetic component and those effected often have both male and female relatives 
with adult-onset diabetes, obesity, elevated blood triglycerides, high blood 
pressure and female relatives with infertility, hirsutism and menstrual problems. 
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Hyperinsulin & PCOS 
 One of the major biochemical features of polycystic ovary syndrome is 
insulin resistance accompanied by compensatory hyperinsulinemia. There is 
increasing data that hyperinsulinemia produces the hyperandrogenism of 
polycystic ovary syndrome by increasing ovarian androgen production, 
particularly testosterone and by decreasing the serum sex hormone binding 
globulin concentration. The high levels of androgenic hormones interfere with the 
pituitary ovarian axis, leading to increased LH levels, anovulation, amenorrhea, 
recurrent pregnancy loss, and infertility. Hyperinsulinemia has also been 
associated high blood pressure and increased clot formation and appears to be a 
major risk factor for the development of heart disease, stroke and type II diabetes. 
Diagnosis  
 Physicians consider diagnosis after making sure that do not have other 
conditions such as Cushing's disease, thyroid problems, congenital adrenal 
hyperplasia or increased prolactin production by the pituitary gland. TSH, 17-
hydroxyprogesterone, prolactin and a dexamethasone suppression test may be 
advisable. Irregular or absent menstrual periods, clues from the physical exam will 
be considered. Height and weight is noted along with any increase facial or body 
hair or loss of scalp hair, acne and acanthosis nigricans. Elevated androgen levels, 
testosterone help make the diagnosis.  
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Newer Methods Of Treatment  
 Traditional treatments have been difficult, expensive and have limited 
success when used alone. Infertility treatments include weight loss diets, ovulation 
medications (clomiphene, letrozole, Follistim, Gonal-F), ovarian drilling surgery 
and IVF. Other symptoms have been managed by anti-androgen medication. 
Ovarian drilling can be performed at the time of laparoscopy.  
 A laser fibre or electrosurgical needle is used to puncture the ovary 10-12 
times. This treatment results in a dramatic lowering of male hormones within days. 
Studies have shown that up to 80% will benefit from such treatment. Many who 
failed to ovulate with letrozole or metformin therapy will respond when 
rechallenged with these medications after ovarian drilling. Interestingly, women in 
these studies who are smokers, rarely responded to the drilling procedure. Side 
effects are rare, but may result in adhesion formation or ovarian failure if the 
procedure is performed by an inexperienced surgeon.  
 For women in the reproductive age range, polycystic ovary syndrome is a 
serious, common cause of infertility, because of the endocrine abnormalities which 
accompany elevated insulin levels. There is increasing evidence that this 
endocrine abnormality can be reversed by treatment with widely available 
standard medications which are leading medicines used in this country for the 
treatment of adult onset diabetes, metformin 500 or 850 mg three times per day or 
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1000mg twice daily with meals, pioglitazone 15-30 mg once a day, rosiglitazone 
4-8 mg once daily or a combination of these medications.  
 These medications have been shown to reverse the endocrine abnormalities 
seen with polycystic ovary syndrome within two or three months. They can result 
in decreased hair loss, diminished facial and body hair growth, normalization of 
elevated blood pressure, regulation or menses, weight loss, reduction in 
cardiovascular risk factors, normal fertility, and a reduced risk of miscarriage. We 
have seen pregnancies result in less than two months in woman who conceived in 
their very first ovulatory menstrual cycle. By six months over 90% of women 
treated with insulin-lowering agents, diet and exercise will resume regular menses. 
Miscarriage & PCOS  
 Women with PCOS who conceive either spontaneously or after ovulation 
induction have a much higher risk of miscarriage. Hypersecretion of LH was 
thought to cause chromosomally abnormal eggs leading to an increased risk of 
miscarriage. Hyperinsulinemia may be a contributing factor in the higher rate of 
miscarriage. Elevated levels of insulin interfere with the normal balance between 
factors promoting blood clotting and those promoting breakdown of the clots. 
Increases in plasminogen activator inhibitor activity associated with high insulin 
levels may result in increased blood clotting at the interface between the uterine 
lining and the placenta. This could lead to placental insufficiency and miscarriage. 
 Obesity, especially central adiposity, is present in around 40% of women 
with PCOS and a greater degree of obesity is associated with a more severe form 
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of PCOS. There is also a higher incidence of metabolic syndrome amongst women 
with PCOS than in non-PCOS overweight and obese women. Weight loss in the 
overweight/obese woman is therefore fundamental to treating the condition. 
PCOS TREATMENT 
1. Medications to Regulate the Menstrual Cycle 
 The most common form of PCOS treatment is the contraceptive pill or birth 
control pill; Even if not sexually active, birth control pills may be prescribed by 
health care provider because they contain the hormones that body needs to treat 
PCOS. These birth control pills help in: 
• Correct the hormonal imbalance  
• Regulate menstrual periods  
• Lower the risk of endometrial cancer (which is slightly higher in young 
women who don't ovulate regularly)  
• Prevent an unplanned pregnancy if sexually active  
• They may also improve androgen-related acne problems, male-type hair 
growth, and male-pattern hair loss.  
2. Medications to Reduce Insulin Resistance 
 Metformin is only FDA-approved treatment for insulin resistance and 
diabetes. Metformin is a useful medication in PCOS patients as it helps to improve 
fertility, reduce miscarriages and gestational diabetes, and reduce long-term health 
problems. The use of metformin in pregnancy remains controversial although the 
risk appears to be small.  
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3. Infertility Medications 
 In PCOD patients suffering from Infertility, the main aim of using 
medications is to make sure there is ovulation happening. Clomid or Letroze are 
the first line of medication used in treatment of infertility in PCOD patients which 
help in ovulation. Patients are educated about fertile period and with the help of 
ovulation prediction kits they are advised to have intercourse. This might not be 
helpful in PCOD patients with persistent high LH levels.  
 Because of the connection between PCOS and insulin resistance, 
medications that are normally used to treat diabetes, namely Metformin, may be 
used to increase insulin sensitivity. By increasing the body's response to insulin, it 
is thought that the ovary may not make as many androgens, which increases the 
likelihood that ovulation will occur. Metformin may also reduce the levels of 
circulating androgens, even if not trying to conceive. This will help regulate 
menstrual cycle and reduce the distressing symptoms that may be experiencing. 
Some women may need to take both Clomid and Metformin in order to ovulate.  
 In cases where oral medication is a failure, hormonal injections like 
Gonadotrophins are used. Each month, Gonadotrophins namely Follicle 
Stimulating Hormone (FSH) is secreted by the pituitary which makes an egg / 
follicle grow. Hence, Gonadotrophin injections directly increase the amount of 
FSH circulating in the body, promoting the growth and development of a mature 
egg. There is a risk of ovarian hyperstimulation when PCOD patients receive 
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gonadotrophin injections; therefore it's mandatory to monitor progress through 
ultrasound and blood tests.  
Surgical Role In PCOD Patients 
 Surgery has got a minimal role in PCOD patients. However, therapeutic 
ovarian drilling can be performed where in the cysts of the ovary are punctures 
under laparoscopic guidance. This treatment results in a dramatic lowering of male 
hormones within days. Studies have shown that up to 80% will benefit from such 
treatment. Women who failed to ovulate with letrozole or metformin therapy will 
respond when rechallenged with these medications after ovarian drilling. 
Interestingly, women in these studies who are smokers rarely responded to the 
drilling procedure. Pelvic adhesions or ovarian failure are few of the side effects 
that can be rarely anticipated after laparoscopic ovarian drilling.  
Role Of Assisted Reproduction In Pcod Patients 
When medical and surgical line of treatments has failed assisted reproductive 
techniques like IUI or In Vitro Fertilization are the next options to be considered. 
Success (pregnancy) rates with IVF in PCOS patients are generally excellent, 
although a higher risk of Ovarian Hyperstimulation exists, especially in IVF 
patients who become pregnant.  
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MATERIALS AND METHODS 
Procurement of Experimental Animal  
 Mice of either sex of wistar strain weighing 28-32gms and Female albino 
rats of wistar strain weighing about 95–135 gm were used. Pregnant animals were 
excluded. Animals were fed on conventional diets and water ad libitum and they 
were maintained under standard conditions of humidity, temperature (20- 24°C) 
and light (12 h light: 12 h dark cycle). Animals were kept in polycarbonate cages 
with laced steel roofs. The rats were acclimatized for 15 days to the laboratory 
conditions prior to experiments and were maintained on the balanced diet, and 
water was provided ad libtum. The study was conducted at the Vel’s University, 
Chennai after obtaining Institutional Animals Ethical Committee clearance bearing 
the number XIII/VELS/PCOL/03/2000/CPCSEA/IAEC/08.08.2012. 
Preparation of stock solution and drugs 
 For ovulatory studies, Soothagathai Udaikkum Kasayam was freshly 
prepared, concentrated and dilutions were prepared at different concentrations and 
administered orally. All the chemicals and standard drugs were procured from 
authorized suppliers. 
Acute toxicity study: 
 Acute oral toxicity test was carried out as per OECD Guidelines 425 up and 
down method. Animals are observed individually after dosing at least once during 
the first 30 minutes, periodically during the first 24 hours, with special attention 
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given during the first 4 h, and daily thereafter, for a total of 14 days. Initially 
starting at a dose of 5ml/kg of Soothagathai Udaikkum Kasayam was given. Body 
weight and behavioral changes were noted. Animals are observed individually and 
were systematically recorded.  
Preparation of Vaginal Smear  
 For taking vaginal smear, the animals were held with ventral side up. A 
drop of 0.9% w/v normal saline was inserted carefully in to the vagina with a 
dropper, without damaging the vagina to avoid false positive smears. The drop of 
normal saline was aspirated and introduced twice, before withdrawing from vagina 
the withdrawn fluid was transferred on to a microscopic glass slide. A cover slip 
was placed carefully on the smear avoiding the entry of air bubbles. The slide was 
then observed under an optical microscope. 
Ovulation stimulation activity 
 In the present study, the study was conducted on twenty four mature virgin 
female Wistar Albino rats weighing of around (88- 130 gm) of 2 month old were 
obtained from the animal house at Vel’s University, Chennai. Before starting drug 
treatment, the reproductive cycles of the rats were synchronized by the following 
method. 100µg estradiol dissolved in 2 ml olive oil was injected subcutaneously. 
All rats after a 24 hr period, received intramuscular injections of 50 µg 
progesterone dissolved in olive oil. After few hours, Vaginal smears were obtained 
by vaginal lavage to monitor ovulation and oestrous cycle. Vaginal smears were 
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prepared by washing vaginal opening with 0.9% w/v of sodium chloride with a 
glass dropper and placed in a clean glass slide and viewed under light microscope 
at 40X magnification. Examination of vaginal smears showed that all the animals 
were in the estrous stage. All the animals were weighed daily after drug 
administration for 10 days. The suitable sensitive rats were divided into four 
groups of six each as follows:  
Group I Normal Control animals given only 2ml/kg of CMC solution.  
Group II animals were administered 5ml/kg of Soothagathai Udaikkum Kasayam 
for 10days,  
Group III rats were received 10mg/kg of Soothagathai Udaikkum Kasayam for 10 
days  
Group IV received clomiphene 10mg/kg and served as standard. All the drugs 
were given orally. 
 2ml of blood was collected by retro orbital puncture. Blood samples were 
centrifuged for 15 minutes at 4000 rpm and the separated serum samples were 
frozen at -20°C and kept for later estimation of LH, FSH and estradiol by ELISA 
method. To study the cycle pattern, animal showing regularity in three normal 
cycles were separated and chosen for further studies. Animals were sacrificed 
24hrs after the last dose. Ovary and uterus were dissected out from adhering 
tissues adhering moisture was removed by pressing gently between two layers of 
filter papers and were immediately weighed on single pan electronic balance. For 
biochemical studies the blood was collected by retro orbital puncture. The 
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collected blood was used for estimating serum FSH, LH and estrogen level. At the 
end of experiment, the animals were sacrificed using ether anesthesia and the uteri 
were removed and weight was recorded. The oviduct was dissected out from the 
rats, suspended in normal saline and placed on a microscopic slide with a cover 
slip to count the number of ova analysis.  
(b) Classification of ovarian follicles for analysis 
 Follicles were classified as primary, small preantral, large preantral, small 
antral and graffian according to the morphological classification scheme. Follicles 
were classified as atretic if they displayed two or more of the following criteria 
within a single cross-section: more than two pyknotic nuclei in the granulosa cell 
layer, granulosa cells and cell debris within the antral cavity, fragmented oocyte 
and granulosa cells pulling away from the basement membrane. 
Histological analysis 
 At the end of the treatment, the ovary was removed and placed in formalin 
fixative for 20-24 hours. Fixed tissue samples were placed in ascending 
concentrations of alcohol and embedded in paraffin. Slices of tissue, 5-7 µm thick, 
were prepared and stained with hematoxylin and eosin, and then monitored and 
evaluated with a light microscope. To study folliculogenesis all tissue blocks were 
serially sliced. Follicle identification was based on the detection of a nucleus. The 
numbers of follicles (primordial, primary, etc.) were counted. Follicle recognition 
criterion on the slides was based on the type of epithelial cells surrounding them. 
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For example, primordial follicles have squamulose cells whereas primary follicles 
are surrounded by cuboidal cells. The numbers of follicles per slide were ran-
domly counted. 
Statistical analysis  
 The data were statistically analyzed and expressed as mean ± SEM. 
Statistical analysis of the variance between control and experimental values was 
done using Student's t test 
RESULTS AND DISCUSSION 
 Results of acute toxicity study revealed that the Soothagathai Udaikkum 
Kasayam nontoxic effect upto 10ml/kg orally. Hence the therapeutic dose was 
selected as 5 and 10ml/kg in rats as higher and lower dose for the further 
pharmacological investigations. In this study, the total number of follicles were 
18.2 ± 3.42 in test group-I (5ml/kg Soothagathai Udaikkum Kasayam), 21.5 ± 3.88 
in test group-II (10ml/kg Soothagathai Udaikkum Kasayam), 28.21 ± 5.56 in 
standard group and 15.32 ± 3.4 in normal group (2ml/kg Saline). There were 
significant increase in ova population in the experimental groups compared to the 
control groups (p<0.01). There were no significant differences between the 
Soothagathai Udaikkum Kasayam concentrations. Similarly a significant increase 
was observed in the number of graffian, antral and multilaminar follicles (p<0.05) 
in the Soothagathai Udaikkum Kasayam groups, but there was no significant 
difference between the 5 and 10ml/kg doses of Soothagathai Udaikkum Kasayam. 
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There was no significant difference in the number of unilaminar primary follicles 
between the test groups and control groups.  
 Estrogens are steroid hormones which, together with other hormones, 
control the ovulatory cycle in the female mammal. Estrogen acts in a feedback 
mechanism, influencing the production of follicle stimulating hormones (FSH) 
from the pituitary gland. It is known that the FSH in turn promotes the 
development of the immature ovarian follicles, which increases the production of 
estrogen from the ovary. There is no scientific report on the effect of Soothagathai 
Udaikkum Kasayam on the ovary. In female rats, oral administration of 
Soothagathai Udaikkum Kasayam for ten days increased the weight of the 
mammary glands, oviduct, endometrium, myometrium, cervix and vagina. In the 
present study, the Soothagathai Udaikkum Kasayam has significantly induced an 
increase in the numbers of graffian, antral and multilaminar primary follicles and 
improved folliculogenesis in rat ovaries.  
 Histological sections of control and experimental groups showed increased 
numbers of growing follicles in the Soothagathai Udaikkum Kasayam groups. 
Present findings indicate that the administration of the Soothagathai Udaikkum 
Kasayam showed significant decrease in the estrogen level and induce stimulatory 
effect on FSH and LH resulting in initiate to ovulate. This can result from 
hypersecretion of gonadotropic hormones, in which case the intensity of the 
hormonal stimuli is sufficient to cause ovulation, or it can result from normal 
ovaries that will allow ovulation.  
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CONCLUSION 
 The present study elucidated that the Soothagathai Udaikkum Kasayam has 
a folliculogenesis effect in female rats consistent with its use in traditional 
medicine as a fertility enhancing agent. These actions may be attributed to the 
alterations in hormonal levels. 
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Table 1: Effect of Soothagathai Udaikkum Kasayam on uterus, ovary and 
body weight of female rats 
Treatment  Dose mg/kg Body weight 
(mg) 
Ovary (mg) Uterus (mg) 
Control 
Saline 
2ml/kg 154.7 ± 8.9 26.8 ± 0.14 97.5 ± 4.2 
Test-I SUK 5ml/kg 150.2 ± 6.5 41.7 ±5.32 206.9 ± 5.0** 
Test-II SUK 10 ml/kg 162.1 ±7.2 52.2 ± 9.41* 235.4 ± 6.4** 
Clomiphene 10mg/kg 167.4 ± 6.4 66.5 ± 7.18** 274.6 ±9.2** 
Values were expressed as Mean±SEM; *P<0.05; **P<0.01. N=6 
Table 2: Effect of Soothagathai Udaikkum Kasayam on hormone levels in 
female rats 
Treatment  Dose mg/kg FSH (Pg/ml) LH (Pg/ml) Estrogen 
(Pg/ml) 
Control Saline 2ml/kg 0.182 ± 
0.004 
0.16 ± 0.05 46.44 ±1.45 
Test-I SUK 5ml/kg 0.161 ± 
0.004* 
0.13 ±0.09 54.38 ± 
1.57* 
Test-II SUK 10 ml/kg 0.132 
±0.005** 
0.10 ± 0.08 63.56 ± 
1.77** 
Clomiphene 10mg/kg 0.124 ± 
0.007** 
0.08 ± 0.03 67.27 ± 
2.82** 
Values were expressed as Mean±SEM; *P<0.05; **P<0.01. N=6 
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ANNEXURE –IV 
Bio Statistical Analysis 
Treatment for Soothaga Vaayu 
The most popular statistical tool, namely, Fisher’s Exact Test analysis has 
been employed to analyses the effectiveness with the help of a hypothesis. 
Hypothesis 
There is no reducing symptoms among the patients for the treatment of 
Soothaga Vaayu. 
 
 
 
Symptoms 
Number of Cases 
Reduced Not Reduced 
Primary 14 
87.5% 
2 
12.5% 
Secondary 1 
25% 
3 
75% 
 
Note:  
Primary: Irregular Menstruation, amenorrhoea, dysmenorrhoea, oligomenorrhoea 
Secondary: Constipation, Infertility. 
Software: spss17 version 
Number of cases: 20 
Test: Fisher’s Exact test 
Confidence Interval: 95% 
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Result: 
P Value (2 tailed): p<0.05 
Inference:  
Since the p value is significant (<o.o5), The hypothesis is not accepted. So there is 
significant reduced symptoms among the patients for the treatment of Soothaga 
Vaayu. Hence it is concluded that the treatment was effective and significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 132  
ANNEXURE –V 
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø ÀÊÅõ 
 
           ¾¢Õ. ___________________________¬¸¢Â ¿¡ý 
___________ÅÂÐ,         
(___________________________________________________________
__________________________________________________________Å
º¢ìÌõ þ¼õ.) ±ý ÍÂ ¿¢¨É×¼ý ±Ø¾¢ì ¦¸¡ÎìÌõ ´ôÒ¾ø ÀÊÅõ. 
  
          ¿¡ý Ý¾¸Å¡Ô ±ýÛõ §¿¡Â¡ø À¡¾¢ì¸ôÀðÎ ¦ºý¨É,«ÃÍ º¢ò¾ 
ÁÕòÐÅ ¸øæ¡¢Â¢ø (þ¼õ: «È¢ï÷ «ñ½¡ þó¾¢Â ÁÕòÐÅÁ¨É, 
«ÕõÀ¡ì¸õ, ¦ºý¨É-106.) ¿¼ò¾ôÀÎõ º¢ò¾ ÁÕòÐÅ ¬Ã¡öîº¢ ãÄõ 
º¢¸¢î¨º ¦ÀÈ ±ý ÍÂ ¿¢¨É×¼ý ÓØºõÁ¾ò¨¾Ôõ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
          þó¾ ¬Ã¡öîº¢Â¢ý §¿¡ì¸õ, ÁÕòÐÅõ ¦ºöÔõ Ó¨È, ¦¾¡¼÷¸ñ¸¡½¢ôÒ 
ÁüÚõ ±ý ‾¼ø ¿Äõ ÌÈ¢ò¾ ÁÕòÐÅ À¡¢§º¡¾¨É¸¨Çô ÀüÈ¢Â Å¢¡¢Å¡É 
Å¢Çì¸õ ±ÉìÌ ÁÕòÐÅõ ¦ºöÔõ ÁÕòÐÅ÷ ãÄõ ¦¾Ç¢×ÀÎò¾ôÀðÎûÇÐ. 
þó¾ ¬Ã¡öîº¢Â¢ø ÀíÌ¦¸¡ûÙõ ±ý ºõÁ¾ò¾¢üÌ Â¡Õ¨¼Â ¿¢÷Àó¾Óõ 
¸¡Ã½Á¢ø¨Ä±ýÀ¨¾ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
 
þôÀÊìÌ, 
 
 
 
¦ÀÂ÷     : 
Ó¸Å¡¢  : 
¿¡û      : 
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CONSENT FORM 
 
          I certify that I have disclosed all the details about the study in the terms 
readily understood by the patient.  
 
DATE :                                                                        SIGNATURE  
                                                                                     NAME 
CONSENT BY THE PATIENT 
           I have been informed to my satisfaction by the attending physician for the 
purpose of the clinical trial and the nature of the drug treatment and follow up 
including the lab investigation to be performed to monitor and safeguard my body 
functions. 
 
           I am aware of my right to opt out of the trial at any time during  
 the course of the trial without having to give reasons for doing so. 
 
           I ,exercising my free power of choice, here by  give my consent to be 
included as a subject in the clinical trial of soothagathai  udaikkum  kasayam  
and Maeni Lavana Chooranam   for the treatment of   
SOOTHAGA  VAAYU. 
 
 
 
 DATE:                                                                                       SIGNATURE   
                                                                                                    NAME                    
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ANNEXURE –VI 
CASE SHEET  
POST GRADUATE DEPARTMENT - BRANCH-I 
 (POTHU) MARUTHUVAM  
GOVT. SIDDHA MEDICAL COLLEGE & ANNA HOSPITAL, CHENNAI-106. 
CASE SHEET PROFORMA FOR “SOOTHAGA VAAYU” 
WARD NO. : NATIONALITY : 
O.P. NO : RELIGION : 
BED NO : OCCUPATION : 
NAME : INCOME : 
AGE : D.O.A : 
SEX : D.OD                               : 
PERMANENT ADDRESS    :  
  DIAGNOSIS : 
 
TEMPORARY ADDRESS:  
Govt. Siddha Medical College & 
Anna Hospital, Chennai – 106.                            MEDICAL OFFICER : 
 
 
 
 
 
COMPLAINTS AND DURATION: 
 
 
 
 
 
HISTORY OF PRESENT ILLNESS: 
 
 
 
 
HISTORY OF PAST ILLNESS: 
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FAMILY HISTORY: 
 
 
PERSONAL HISTORY & HABITS : 
A. Food    : Veg   Non veg 
B. Marital status    : single    married 
C. Duration of married life : 
D. Gravid                                     : 
E. Para                                         : 
F. Live                                         : 
G. Abortion                                  : 
MENTRUAL HISTORY: 
A. Regularly of cycle   : Regular   Irregular  
B. Length of cycle [Days] : 
C. Duration of flow[Days] : 
D.  Level of flow   :  low  moderate heavy 
E. Abdominal pain   : nil  mild  moderate severe  
F. LMP             : 
 
 
GENERAL EXAMINATION: 
 
1. Physical build                      :      lean             normal            obese         
2. Height                                      : 
3.  Body weight                          :   
4. Temperature  : 
5. Pulse rate : 
6. Heart rate : 
7. Respiratory rate : 
8. Blood pressure  : 
9.  Pallor   : 
10. Cyanosis  :   present               absent      
11.  Jaundice :   present               absent     
12. Clubbing  :   present               absent 
13. Pedal oedema :   present               absent 
14. Lymphadenopathy   :   present               absent 
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EXAMINATION OF VITAL ORGANS 
1.Heart : 
2.Lungs : 
3.Abdomen and pelvis : 
               
              Inspection: 
  Palpation:   
 Tenderness Present  absent  
 Mass   Present  absent 
 
SIDDHA ASPECTS 
Yaakai (udal nilai)      Mukkunam  
1. Vatham        1. Sathuva gunam 
2. Pitham       2. Raasatha gunam  
3. Kabham       3. Thamo gunam 
4.Kalappu 
 
PARUVA KAALAM (SEASONS)  NILAM (PLACES) 
1. Kaar Kaalam         (Aavani-Puratasi) Aug-sept.   1.Kurinchi (Hills  Areas) 
2. Koothir Kaalam     (Iypasi-Karthigai) Oct-Nov. 2.Mullai (Forest Areas) 
3. Munpani  Kaalam  (Maargazhi-Thai) Dec-Jan. 3.Marudham (Fertile Areas) 
4. Elavenil Kaalam    (Chithirai-Vaikasi) Apr-May 4.Neithal (Sea Areas) 
5. Mudhuvenil  Kaalam (Aani-Aadi) Jun-Jul 5.Paalai (Desert Areas) 
 
AIYMPORIGAL/PULANGAL  KANMENTHIRIYAM / 
KANMAVIDAYAM 
1. Mei  (Sensation)  1.Kai [Koduthal] 
2. Vaai (Taste)  2.Kaal [Nadathal] 
3. Kann  (Vision)  3.Vaai [Pesal] 
4.  Mooku(Smell)  4.Eruvai [Malam Kazhithal] 
5. Sevi (Hearing) 5.Karuvai [Aananthithal] 
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UYIR THATHUKKAL: 
 VATHAM: 
1. Pranan   6.  Naagan 
2. Abanan   7.  Koorman 
3. Viyanan   8.  Kirukaran 
4. Udhanan   9.  Devadathan 
5. Samanan  10. Dhananjeyan 
PITHAM:   KAPHAM: 
1. Anal Pitham  1.  Avalambagam 
2. Ranjaga Pitham   2.  Kledagam 
3. Saadhaga Pitham   3.  Podhagam 
4. Aalosaga Pitham   4.  Tharpagam                                  
5. Prasaga Pitham  5.  Santhigam 
UDAL THATHUKKAL: 
1. Saaram 
2. Senneer 
3. Oon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam / Suronitham 
ENVAGAI THERVU: 
1. Naa -  
2. Niram              - 
3. Mozhi -  
4. Vizhi -  
5. Sparisam         - 
6. Malam              
                   a. Niram 
                   b.Nurai 
                   c.Erugal   
                   d.Elagal 
 
7. Moothiram 
         1) Neerkuri  
                   a. Niram 
                   b.Edai 
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                   c.Manam  
                   d.Nurai 
                   e. Enjal 
   2)Neikuri 
      8.Naadi  
 
SIGNS AND SYMPTOMS 
   PRESENT ABSENT  
 
1. Irregular menstruation  - 
2. Oligomenorrhoea          - 
3. Amenorrhoea              - 
4. Dysmenorrhoea            -      
5. Constipation                 - 
6. Infertility                       - 
 
                
 
Assessment: 
Clinical features Before 
Treatment 
After Treatment 
I II III IV 
Regularly of cycle      
Length of cycle      
Duration of flow      
Level of flow      
Abdominal pain and 
low back pain 
     
Constipation      
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LABORTORY INVESTIGATIONS: 
   BT AT 
1.Blood   
   Tc 
   Dc 
   ESR 
   Hb 
   Bl-sugar (F) 
   Sr.Cholesterol 
   TSH 
    
2.Urine - alb 
   Sug 
   Dep 
 
3.USG – PELVIS 
 
TRAIL DRUGS: 
Drug 1: 
 
Dose: 
 
Drug 2: 
 
Dose: 
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Adjuvent: 
 
Diet: 
 
Duration of treatment: 
 
Pathiam (Do’s and Don’ts): 
 
Prognosis at the end of the treatment 
 
 
Medical Officer Signature:  H.O.D 
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LABORATORY INVESTIGATION REPORT (O.P) 
 
S. 
No
. 
OP 
No. 
Name  
Age /Sex 
Before Treatment After treatment ESR (mm) 
 
HB  
(gm) 
Blood 
Sugar(F) 
S.Cholestrol 
mg% 
               Urine Analysis  
   BT                                     AT 
TC 
Cells/ 
cumm 
DC TC 
Cells/ 
cumm 
DC BT AT BT AT BT AT BT AT Alb Sug Dep Alb Sug Dep 
P 
% 
L 
% 
E 
% 
P 
% 
L 
% 
E 
% 
½ 
hr 
1 
hr  
½ 
hr 
1 
hr  
1. 1334 Samundeeswari 
24/F 
9000 53 41 6 9100 58 38 4 23 52 12 25 10
.8 
11 84 82 153 154 Nil  Nil FEC Nil Nil Nil  
2. 2859 Kavitha 
28/F 
8400 54 42 4 8600 54 40 4 20 50 15 30 8.
4 
9 88 89 150 153 Nil Nil OPC Nil Nil Nil 
3. 3509 Priya 
22/F 
10000 62 33 2 10200 60 33 2 35 72 20 40 8 10 98 96 170 174 Nil Nil OPC Nil Nil Nil 
4. 4220 Srileka 
19/F 
8600 55 41 4 8200 52 42 6 21 40 15 30 11 11 83 82 148 150 Nil Nil OPC  Nil Nil Nil 
5. 6446 Gowri 
21/F 
9200 61 35 4 9200 64 29 4 31 61 15 30 11
.8 
12 83 80 152 155 
 
Nil Nil FEC Nil Nil Nil 
6. 9528 Chitra 
17/F 
9400 55 41 4 8000 52 44 5 4 80 20 40 13 12 88 85 150 149 Nil Nil FEC Nil Nil Nil 
7. 1218 Saranya 
21/F 
10400 62 34 4 10600 58 38 4 21 44 15 30 11 11 80 78 153 155 Nil Nil OEC Nil Nil Nil 
8. 6193 Mary 
21/F 
9400 52 48 8 9500 54 36 4 12 21 11 20 10
.8 
11 83 85 150 152 Nil Nil OEC Nil Nil Nil 
9. 5125 Arunthathi 
21/F 
9800 63 33 3 9800 62 34 3 15 30 12 25 12 12 80 86 149 150 Nil Nil Nil Nil Nil Nil 
10. 5494 Karppagam 
29/F 
8700 55 39 6 8600 54 40 6 8 10 10 12 8.
8 
9 82 84 154 155 Nil Nil Nil Nil Nil Nil 
 11. 6825 Sabana 
26/F 
8400 53 42 8 8300 53 42 5 6 11 5 10 10 11 70 72 150 149 Nil Nil FEC Nil Nil Nil 
12. 7325 Haritha 
19/F 
8000 57 36 7 8100 58 35 7 23 55 11 22 7.
8 
9 75 74 158 155 Nil Nil Nil  Nil Nil Nil 
13. 032 Punitha 
24/F 
8100 53 43 4 8000 58 38 4 15 30 10 15 11 10.
2 
83 80 158 152 Nil Nil FEC Nil Nil Nil 
14. 9999 Umamageswari 
29/F 
10700 60 34 6 10700 58 36 6 5 10 5 10 12
.6 
12 84 85 149 150 Nil Nil Nil  Nil Nil Nil 
15. 2528 Chitra 
25/F 
9800 57 39 4 9600 58 38 4 15 30 10 15 11 12 73 80 165 163 Nil Nil OEC Nil Nil Nil 
16. 4349 Keerithika 
17/F 
9000 57 38 5 9800 58 38 4 9 15 8 10 11
.8 
11 83 80 159 160 Nil Nil Nil  Nil Nil Nil 
17. 6781 Kavitha 
24/F 
9200 57 40 3 8400 58 39 3 21 20 10 15 12
.4 
10 87 85 159 162 Nil Nil FEC Nil Nil Nil 
18. 7211 Punithavathi 
19/F 
9800 60 34 6 10000 58 36 6 44 88 20 35 11 11 83 78 153 150 Nil Nil OEC Nil Nil Nil 
19. 5903 Sudha 
28/F 
7900 55 39 6 7900 56 38 6 18 40 15 30 8 9 88 86 155 155 Nil Nil OPC Nil Nil Nil 
20. 4064 Kanchana 
34/F 
8000 58 38 4 8500 58 38 4 44 95 22 44 8 9 76 85 158 161 Nil Nil OEC Nil Nil Nil 
 
 
 
 
 
 
 
 
 
  
USG-ABDOMEN & PELVIS REPORTS 
 
 
 
S.No. OP No. Name 
Age/Sex 
USG/Scan 
(Pcos) 
1.  1334 Samundeeswari 
24/F 
Bilateral 
2.  2859 Kavitha 
28/F 
Bilateral 
3.  3509 Priya 
22/F 
Bilateral 
4.  4220 Srileka 
19/F 
Bilateral 
5.  6446 Gowri 
21/F 
Bilateral 
6.  9528 Chitra 
17/F 
Bilateral 
7.  1218 Saranya 
21/F 
Bilateral 
8.  6193 Mary 
21/F 
Unilateral 
9.  5125 Arunthathi 
21/F 
Bilateral 
10.  5494 Karppagam 
29/F 
Bilateral 
11.  6825 Sabana 
26/F 
Bilateral 
12.  7325 Haritha 
19/F 
Bilateral 
13.  032 Punitha 
24/F 
Bilateral 
14.  9999 Umamageswari 
29/F 
Bilateral 
15.  2528 Chitra 
25/F 
Bilateral 
16.  4349 Keerithika 
17/F 
Bilateral 
17.  6781 Kavitha 
24/F 
Bilateral 
18.  7211 Punithavathi 
19/F 
Unilateral 
19.  5903 Sudha 
28/F 
Bilateral 
20.  4064 Kanchana 
34/F 
Bilateral 
 
 
 
 
 
FEMALE REPRODUCTIVE SYSTEM 
 
 
INTERNAL GENITALIA 
 
 
 OVARIES 
 
 
 
 
 
 
 
 
 
 
 ENDOMETRIAL CYCLE 
 
 
 
 
 
 
 
 
 MENSTRUAL CYCLE 
 
 
HISTOPATHOLOGY 
 
BRAIN 
 2.5ml    5ml    10ml 
         
 
BONE 
2.5ml    5ml    10ml 
         
      
HEART 
2.5ml    5ml    10ml  
          
 
INTESTINE 
2.5ml    5ml    10ml 
          
 
 
KIDNEY 
2.5ml    5ml    10ml 
         
 
LIVER 
2.5ml    5ml    10ml 
         
 
LUNG 
2.5ml    5ml    10ml 
         
 
OVARY 
2.5ml    5ml    10ml 
         
 
 
 
 
PANCREAS 
2.5ml    5ml    10ml 
         
 
SPLEEN 
2.5ml    5ml    10ml 
         
 
STOMACH 
2.5ml    5ml    10ml 
         
 
TESTIS 
2.5ml    5ml    10ml 
         
 
 
TRIAL DRUG: 1 SOOTHAGATHAI UDAIKKUM 
KASAYAM 
 
     OOMAM                SITHIRAMOOLA VAER  
  
 CHATHAKUPPAI                             SITHIRAMOOLA VAERPATTAI 
                        
    CHUKKU      PARANGI SAKKAI 
                       
 
THIPPILI      MAAVILANGA PATTAI 
                      
KARUNJEERAGAM    MOONGILILAI 
                                                                     
 
         
   
 
 
 
 
 
TRIAL DRUG-2: MAENI LAVANA CHOORANAM 
 
    CHUKKU       INDHUPPU 
                       
OOMAM       SOTRUPPU 
                    
PERUNGAYAM      KUPPAIMNENI 
                 
 
 
DRUG:1 
SOOTHAGATHAI UDAIKKUM KASAYAM 
 
DRUG:2 
MAENI LAVANA CHOORANAM 
 
 


